1. GBOU HPE " Moscow state medical and dental University. Evdokimova (Moscow, Russia)
2. northwestern state medical University named After I. I. Mechnikov, Ministry of health of Russia (St. Petersburg, Russia)
3. GAUSS "Republican clinical hospital" MZ RT (Kazan, Russia)
4. doctor of Kazan state medical University of Minzdrav of Russia (Kazan, Russia)
5. Federal STATE Autonomous educational institution "Kazan (Volga region) Federal University" (Kazan, Russia)
6. fgbu DPO", UNMC" UD prezidenta RF (Moscow, Russia)
7. FSBEI Omsk state medical University of Minzdrav of Russia (Omsk, Russia)
8. INSTITUTION Moscow Clinical Scientific Center DZM (Moscow, Russia)
9. Federal state budgetary institution "polyclinic No. 3" Of the office of the President of the Russian Federation (Moscow, Russia)
10. doctor of Rostov state medical University of Minzdrav of Russia (Rostov-on-don, Russia)
11. SPb GBUZ "Consultative and diagnostic polyclinic № 1" of St. Petersburg (St. Petersburg, Russia)
12. military medical Academy. S. M. Kirov MO of the Russian Federation (St. Petersburg, Russia)
13. Tver state medical University (Tver, Russia)
14. Mordovian state University named after N. P. Ogareva (Saransk, Russia)
15. fsbi "Central clinical hospital with polyclinic" of administrative Department of the President of the Russian Federation (Moscow, Russia)
16. fgbun clinic "FITZ nutrition and biotechnology" (Moscow, Russia)
17. FGBOU DPO RMAPO Ministry of health of Russia (Moscow, Russia)
18. Saratov state medical University. V. I. Razumovsky Ministry of health of Russia (Saratov, Russia)
19. FGBOU VO "Saint-Petersburg state pediatric medical University" (Saint Petersburg, Russia)
20. regional clinical hospital № 2 (Moscow, Russia)
21. "Scientific-research Institute of therapy and preventive medicine" (Moscow, Russia)
22. medical center of the Central Bank of Russia (Moscow, Russia)
23. fgbi "NMHC im. N. I. Pirogova " Ministry of health of Russia (Moscow, Russia)
24. FGBOU DPO RMAPO Ministry of health of Russia (Moscow, Russia)
25. scientific and technical center intersectoral scientific and technical Association (STC ISTO) "Granite" (Moscow, Russia)
26. Novosibirsk state medical University of the Ministry of health of Russia (Novosibirsk, Russia)
27. "Scientific-research Institute of experimental and clinical medicine" (Moscow, Russia)
28. Stgma of the Ministry of health of Russia (Stavropol, Russia)
29. Belarusian state medical University (Minsk, Belarus)
30. all-Russian center for emergency and radiation medicine. A. M. Nikiforov (Moscow, Russia)
31. KSMA - a branch of FGBOU DPO RMAPO Ministry of health of Russia (Kazan, Russia)
32. Ural state Academy of additional education (Ekaterinburg, Russia)
33. inter-District gastroenterological center № 1 of St. Petersburg (St. Petersburg, Russia)
34. BU "Republican clinical hospital" of Chuvashia Ministry of health (Cheboksary, Russia)
35. of the "Perm state medical University named after academician E. A. Wagner" of Ministry of health of Russia (Perm, Russia)
36. Federal state budgetary institution Pushchino scientific center of the Russian Academy of Sciences (Pushchino, Russia)
37. research Institute of medical problems of the North (Krasnoyarsk, Russia)
38. peoples ' friendship University of Russia (Moscow, Russia)
39. clinic of JSC Meditsina (Moscow, Russia)
40. scientific clinical center of physical-chemical medicine of FMBA of Russia (Moscow, Russia)

Abstract:VI NATIONAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ACID RELATED AND HELICOBACTER PYLORI ASSOCIATED DISEASES ( the VI th MOSCOW AGREEMENT) were approved by the XVI Congress of the Scientific Society of Gastroenterologists of Russia in Moscow, November 24-25, 2016. The Guidelines text is in Russian.

• References total 124 ⇓ :: .
  1. Абдулхаков Р. А., Абузарова Э. Р., Абдулхаков С. Р., Сафин А. Г., Сайфутдинов И. М., Чернов В. М., Чернова О. А. Резистентность Helicobacter pylori к кларитромицину в Казани// Экспериментальная и клиническая гастроэнтерология.2012. № 8. С. 24-29.
  2. Агеева Е. А., Харитонова Т. И., Гуляко Л. Ф., Зайнулина З. У., Васильева А. В., Воробьева В. А., Никитин О. Н. Диагностические возможности уреазного дыхательного (хелик) теста в оценке эрадикации helicobacter pylori-инфекции Дальневосточный медицинский журнал. 2010. № 4. С. 12-15.
  3. Бехтерева М. К., Луппова Н. Е., Корниенко Е. А., Минина С. Н., Новикова В. П., Осмаловская Е. А., Приворотский В. Ф., Староверов Ю. И., Ткаченко М. А., Шабалов Н. П., Гончар Н. В., Панфилова В. Н., Ямолдинов Р. Н., Бельмер С. В., Хавкин А. И., Нижeвич А. А. Рабочий протокол диагностики и лечения лямблиоза у детей (принят на XX Конгрессе детских гастроэнтерологов России и стран СНГ, Москва, 19-21 марта 2013 г.). Вопросы детской диетологии, 2013, т. 11, № 6, с. 72-76
  4. Дехнич Н. Н., Костякова Е. А., Пунин А. А., Алимов А. В., Иванчик Н. В., Козлов Р. С. Антибиотикорезистентность H.pylori: результаты микробиологического регионального исследования// Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2011. Т. 21. № 2. С. 37-42
  5. Конаныхина С. Ю., Сердюк О. А., Степанова И. И., Касторина М. Л. Эффективность нифурател-содержащей трехкомпонентной схемы эрадикации Helicobacter pylori у детей и взрослых по результатам определения НР-антигена в пробах фекалий. Инфекционные болзни. 2008. - Т. 6. - № 3. - С. 20-24.
  6. Конорев М. Р., Комлева Е. Н., Кухарев А. В. [и др.]. Оценка эффективности аммиачного дыхательного теста ХЕЛИК для диагностики Helicobacter pylori в желудке и некоторые ошибки при проведении исследования // Практическая медицина. 2015. No 5(90). С. 202-208.
  7. Конорев М. Р., Матвеенко М. Е., Крылов Ю. В., Комлева Е. Н., Коваленко Т. В. Сравнительная оценка эффективности быстрого уреазного теста Хелпил для диагностики Helicobacter pylori в желудке и двенадцатиперстной кишке - Иммунопатология, аллергология, инфектология. - 2012. - No3. - С. 63-72.
  8. Консолар М. Новые подходы к диагностике и элиминации Helicobacter pylori при язвенной патологии желудочно-кишечного тракта.// Автореф. дис\. … канд. биол. наук. Казань, 2007.
  9. Корниенко Е. А., Милейко В.Е., Самокиш В. А., Нажиганов О. Н. Неинвазивные методы диагностики Helicobacter pylori // Педиатрия. 1999. No 1. С. 37-40.
  10. Кудрявцева Л. В. Динамика резистентности штаммов Helicobacter pylori к амоксициллину, кларитромицину и метронидазолу в России с 1996 по 2001 год // Педиатрия. 2002. Т. 2. С. 63-64.
  11. Лазебник Л. Б., Белоусова Н. Л., Бордин Д. С., Михеева О. М., Дубцова Е. А., Воробьева Н. Н., Зеленикин С. А. Резистентность Helicobacter pylori к кларитромицину в Москве и прополис как средство, повышающее эффективность эрадикации // Экспериментальная и клиническая гастроэнтерология. 2012. № 8. С. 10-14.
  12. Леонтьева Н. И. Клинико-патогенетические аспекты хеликобактериоза, диагностика и тактика лечения: дис. … д-ра мед. наук. М.: МНИИЭМ им.Г.Н.Габричевского, 2012. 282 с.
  13. Маев И. В., Сайфутдинов Р. Г., Самсонов А. А., Гречушников В. Б. Результаты открытого мультицентрового исследования эффективности дыхательных тестов в диагностике H. pylori. Дневник казанской медицинской школы. 2013. № 1 (1). С. 21-23.
  14. Мишкина Т. В. Диагностическая значимость метода полимеразной цепной реакции при генотипированииHelicobacter pylori у детей с хронической гастродуоденальной патологией //Автореф. дис. канд. мед. наук. СПб, 2007.
  15. Нижевич А. А. Клинико-морфологическая характеристика, генетические маркеры, диагностика и лечение НР-ассоциированных гастродуоденальных заболеваний у детей // Автореферат дисс. д. м.н., 14.01.08 - педиатрия, 14.01.28 - гастроэнтерология. БГМУ, Москва,
  16. Нижевич А. А., Сатаев В. У., Ахмадеева Э. Н., Арзамасцев А. Г. Тройная нифурател-содержащая антихеликобактерная терапия 1 линии у детей. Blackwell Publishing Ltd, Helicobacter 2007. № 12: 132-135
  17. Осипенко М. Ф., Бикбулатова Е. А., Шакалите Ю. Д., Чернова Л. Н., Устинов С. Н., Куликов И. В., Максимов В. Н. Резистентность Helicobacter pylori к кларитромицину в Новосибирске// Экспериментальная и клиническая гастроэнтерология. 2012. № 8. С. 15-17.
  18. Паролова Н. И. Сравнительная оценка эффективности эрадикационной терапии инфекции Нelicobacter pylori у детей// Автореф. дис. канд. мед. наук. СПб, 2007.
  19. Сарсенбаева А. С., Захарова Н. А. Оптимизация диагностики клинически латентных форм язвенной болезни желудка и двенадцатиперстной кишки у пациентов, состоящих на диспансерном учете // Фундаментальные исследования. 2011. No 2. С. 147-151.
  20. Стандарт первичной медико-санитарной помощи детям при язве желудка и двенадцатиперстной кишки (обострение) МЗ РФ, Приказ 659Н от 7 ноября 2012. Москва.
  21. Суханов А. В., Пикерский И. Э., Сайфутдинов Р. Г., Макаров А. А., Фролов С. В. Сравнительная оценка различных методов диагностики хеликобактерной инфекции // Клиническая и экспериментальная гастроэнтерология. 2011. No 5. С. 8-15.
  22. Успенский Ю. П., Барышникова Н. В. Использование препаратов нитрофуранового ряда в схемах эрадикационной терапии первой линии. Русский медицинский журнал. 2012. - № 25. С. 1-4.
  23. Успенский Ю.П., Барышникова Н. В., Орлов О. Ю., [и др.]. Дыхательный аммонийный тест в диагностике инфекции Helicobacter pylori: преимущества и недостатки // Дневник Казанской медицинской школы. URL: www.dkmsc.ru/gastroenterologiya/item/48-dy-hatel-ny-i-am- monii-ny-i-test-v-diagnostike-infektcii-helicobacter-pylori-preimushchestva-i-nedostatki (дата обращения 08.11.2015 г.)
  24. Федеральные _клинические _рекомендации _по _оказанию _медицинской _помощи детям с _язвенной _болезнью _желудка _и/_или двенадцатиперстой _кишки МЗ РФ и союза_педиатров _России. Москва. - 2015. - 20 с.
  25. Харченко Н. В., Лопух И. Я. Оценка диагностической надежности «ХЕЛИК-теста» для определения инфекции Helicobacter pylori // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. Материалы XIV Российской Гастроэнтерологической недели. 2008. No 5. С. 185.
  26. Эрдес С. И., Логвинова А. И., Русанова Н. М. Нитрофурановые препараты в схемах антихеликобактерной терапии у детей. Доктор.ру. 2013 год № 3 (81). С. 46-50.
  27. Arnold M, Moore SP, Hassler S, et al. The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut 2014;63:64-71.
  28. Baryshnikova N. V., Belousova L. N., Loeva I. A. [et al.]. Comparative Analysis of efficacy of noninvasive ammoni- um “HELIC-test” and histological method in diagnostic of Helicobacter pylori infection // Helicobacter. 2014. V. 19 (S.1). Р. 122.
  29. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150-8.
  30. Chan FKL, Ching JYL, Suen BY, et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013;144:528-35.
  31. Chan FKL, Wong VWS, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;369:1621-6.
  32. Chen HN, Wang Z, Li X, et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer 2016;19:166-75.
  33. Correa P. Serum pepsinogens in gastric cancer screening. Dig Dis Sci 2010;55:2123-5.
  34. Cosme A, Lizasoan J, Montes M, et al. Antimicrobial susceptibility-guided therapy versus empirical concomitant therapy for eradication of Helicobacter pylori in a region with high rate of clarithromycin resistance. Helicobacter 2016;21: 29-34.
  35. Cuadrado-Lavín A, Salcines-Caviedes JR, Diaz-Perez A, et al. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial. J Antimicrob Chemother 2015;70:2376-81.
  36. Dang Y, Reinhardt JD, Zhou X, et al. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One 2014;9: e111030.
  37. Delgado S, Cabrera-Rubio R, Mira A, et al. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb Ecol 2013;65:763-72.
  38. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa. Endoscopy 2012;44:74-94.
  39. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15-24.
  40. Federico A, Nardone G, Gravina AG, et al. Ef ficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012;143:55-61.e1; quiz e13-14.
  41. Feng L, Wen MY, Zhu YJ, et al. Sequential therapy or standard triple therapy for helicobacter pylori infection: an updated systematic review. Am J Ther 2016;23: e880-93.
  42. Fletcher EH, Johnston DE, Fisher CR, et al. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther 2010;32:831-9.
  43. Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348: g3174.
  44. Маев И. В., Сайфутдинов Р. Г., Самсонов А. А., Гречушников В. Б. Результаты открытого мультицентрового исследования эффективности дыхательных тестов в диагностике H. pylori. Дневник казанской медицинской школы. 2013. № 1 (1). С. 21-23.
  45. Fukuchi T, Ashida K, Yamashita H, et al. In fluence of cure of Helicobacter pylori infection on gastric acidity and gastroesophageal reflux: study by 24-h pH monitoring in patients with gastric or duodenal ulcer. J Gastroenterol 2005;40:350-60.
  46. Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347: f4587.
  47. Gisbert JP, Calvet X. Helicobacter pylori ‘test-and-treat’ strategy for management of dyspepsia: a comprehensive review. Clin Transl Gastroenterol 2013;4: e32.
  48. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2011;34:604-17.
  49. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012;5:23-34.
  50. Gisbert JP, Romano M, Molina-Infante J, et al. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Dig Liver Dis 2015;47: 108-13.
  51. Goddard AF, James MW, McIntyre AS, et al. Guidelines for the management of iron deficiency anaemia. Gut 2011;60:1309-16.
  52. González-Pérez A, Sáez ME, Johansson S, et al. Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One 2014;9: e101768.
  53. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-86.
  54. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719-31.
  55. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 2015;54:703-10.
  56. Heo J, Jeon SW, Jung JT, et al. Concomitant and hybrid therapy for Helicobacter pylori infection: a randomized clinical trial. J Gastroenterol Hepatol 2015;30:1361-6.
  57. Holster IL, Valkhoff VE, Kuipers EJ, et al. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013;145:105-112.e15.
  58. Huang YK, Yu JC, Kang WM, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS One 2015;10: e0142080.
  59. Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease. Gut 2015;64:1650-68.
  60. IARC/WHO. Helicobacter pylori eradication as a strategy for preventing gastric cancer. International Agency for Research on Cancer/ World Health Organisation, 2014. “http://www.iarc.fr/en/publications/pdfs-online/wrk8/” www.iarc.fr/en/ publications/pdfs-online/wrk8/ (accessed online Aug 2016).
  61. Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol 2015;30:1338-45.
  62. Kishikawa H, Kimura K, Takarabe S, et al. Helicobacter pylori antibody titer and gastric cancer screening. Dis Markers 2015;2015:156719.
  63. Konorev M. R., Komleva E. N., Matveenko M. E. Evaluation of efficiency of HELIC ammonia breth test for di- agnostics of H. Pylori infection in stomach in rheumatoidartri- tis patients taking NSAIDS // Helicobacter. 2014. V. 19 (S.1). Р.123.
  64. Lanas Á, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015;13:906-12.e2.
  65. Lee ST, Lee DH, Lim JH, et al. Ef ficacy of 7-day and 14-day bismuth-containing quadruple therapy and 7-day and 14-day moxifloxacin-based triple therapy as second-line eradication for Helicobacter pylori infection. Gut Liver 2015;9:478-85.
  66. Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016;150:1113-1124.e5.
  67. Leja M, Kupcinskas L, Funka K, et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci 2011;56:145-50.
  68. Li Y, Huang X, Yao L, et al. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010;122:413-22.
  69. Liang X, Xu X, Zheng Q, et al. Ef ficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013;11:802-7. e1.
  70. Liu WZ, Xie Y, Cheng H, et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis 2013;14:211-21.
  71. López-Góngora S, Puig I, Calvet X, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother 2015;70:2447-55.
  72. Lv Z, Wang B, Zhou X, et al. Ef ficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med 2015;9:707-16.
  73. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-13.
  74. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-64.
  75. Malfertheiner P. Diagnostic methods for H. pylori infection: choices, opportunities and pitfalls. United European Gastroenterol J 2015;3:429-31.
  76. Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis 2011;29:459-64.
  77. McNicholl AG, Forné M, Barrio J, et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur J Gastroenterol Hepatol 2014;26:941-8.
  78. McNicholl AG, Marin AC, Molina-Infante J, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014;63:244-9.
  79. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
  80. Mocellin S, Verdi D, Pooley KA, et al. Genetic variation and gastric cancer risk: a field synopsis and meta-analysis. Gut 2015;64:1209-19.
  81. Modlin I. M., Hunt R. H., Malfertheiner P. et al. Diagnosis and Management of Non-Erosive Reflux Disease - The Vevey NERD Consensus Group // Digestion. - 2009. - Vol. 80. -P. 74-88.
  82. Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015;41:581-9.
  83. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013;145:121-128.e1.
  84. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012;61:507-13.
  85. Nishizawa T, Maekawa T, Watanabe N, et al. Clarithromycin versus metronidazole as first-line Helicobacter pylori eradication: a multicenter, prospective, randomized controlled study in Japan. J Clin Gastroenterol 2015;49:468-71.
  86. Niv Y, Niv G, Koren R. 13C-urea breath test for diagnosis of Helicobacter pylori infection in the elderly. Dig Dis Sci 2004;49:1840-4.
  87. Nocon M, Kuhlmann A, Leodolter A, et al. Ef ficacy and cost-effectiveness of the 13C-urea breath test as the primary diagnostic investigation for the detection of Helicobacter pylori infection compared to invasive and non-invasive diagnostic tests. GMS Health Technol Assess 2009;5: Doc14.
  88. P Malfertheiner, F Megraud, C A O’Morain et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report Gut 2016;0:1-25. doi:10.1136/gutjnl-2016-312288
  89. Gisbert JP, Calvet X. Helicobacter pylori ‘test-and-treat’ strategy for management of dyspepsia: a comprehensive review. Clin Transl Gastroenterol 2013;4: e32.
  90. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
  91. Qu X-H, Huang X-L, Xiong P, et al. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol 2010;16:886-96.
  92. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2009;21:45-53.
  93. Sardarian H, Fakheri H, Hosseini V, et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013;18:129-34.
  94. Selgrad M, Meissle J, Bornschein J, et al. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur J Gastroenterol Hepatol 2013;25:1257-60.
  95. Selgrad M, Meissle J, Bornschein J, et al. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur J Gastroenterol Hepatol 2013;25:1257-60.
  96. Seo J. H., Park J. S. Yeom J. S. et al. Correlation between positive rate and number of biopsy samples on urease test in childhood Helicobacter pylori infection. J Korean Med Sci 2014;29:106-9.
  97. Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol 2013;23(Pt B):492-501.
  98. Sonnenberg A, Lash RH, Genta RM. A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 2010;139: 1894-901.
  99. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010;32:1069-79.
  100. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016;43:514-33.
  101. Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am J Gastroenterol 2015;110:684-9.
  102. Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am J Gastroenterol 2015;110:684-9.
  103. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-67.
  104. Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C 19 genotype. World J Gastroenterol 2014;20:6400-11.
  105. Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:168-74.
  106. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015;41:1237-45.
  107. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010;32:1069-79.
  108. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016;43:514-33.
  109. Tongtawee T, Dechsukhum C, Leeanansaksiri W, et al. Improved detection of Helicobacter pylori infection and premalignant gastric mucosa using “site specific biopsy”: a randomized control clinical trial. Asian Pac J Cancer Prev 2015;16:8487-90.
  110. Tongtawee T, Dechsukhum C, Leeanansaksiri W, et al. Improved detection of Helicobacter pylori infection and premalignant gastric mucosa using “site specific biopsy”: a randomized control clinical trial. Asian Pac J Cancer Prev 2015;16:8487-90.
  111. Vergara M, Catalán M, Gisbert JP, et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-18.
  112. Wang B, Wang YH, Lv ZF, et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015;20:79-88.
  113. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011;83: 253-60.
  114. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013;47:25-32.
  115. Wenzhen Y, Yumin L, Quanlin G, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 2010;49:1103-9.
  116. Wong AYS, Root A, Douglas IJ, et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016;352: h6926.
  117. Wu JY, Hsu PI, Wu DC, et al. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter 2014;19:207-13.
  118. Yang I, Woltemate S, Piazuelo MB, et al. Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. Sci Rep 2016;6:18594.
  119. Yoon H, Lee DH, Kim N, et al. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol 2013;28:1801-9.
  120. Yuan W, Li Yumin, Yang Kehu, et al. Iron de ficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010;45:665-76.
  121. Zhang M-M, Qian W, Qin Y-Y, et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol 2015;21:4345-57.
  122. Zheng X, Lyu L, Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig 2013;105:445-53.
  123. Zhu R, Chen K, Zheng Y-Y, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol 2014;20: 18013-21.
  124. Zullo A, Hassan C, Ridola L, et al. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med 2013;24:16-19.

Full text is published :
VI NATIONAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ACID-RELATED AND Helicobacter Pylori-ASSOCIATED DISEASES (VI Moscow agreement). Experimental and Clinical Gastroenterology Journal. 2017;138(02):03-21
Read & Download full text

1. GBOU HPE " Moscow state medical and dental University. Evdokimova (Moscow, Russia)
2. northwestern state medical University named After I. I. Mechnikov, Ministry of health of Russia (St. Petersburg, Russia)
3. FGBOU VO "Saint-Petersburg state pediatric medical University" (Saint Petersburg, Russia)
4. INSTITUTION Moscow Clinical Scientific Center DZM (Moscow, Russia)
5. military medical Academy. S. M. Kirov MO of the Russian Federation (St. Petersburg, Russia)
6. fsbi "SPFIC im. V. A. Almazov" Ministry of health of Russia (Saint-Petersburg, Russia)
7. GOU DPO St. Petersburg medical Academy of postgraduate education (St. Petersburg, Russia)
8. FEDERAL state budgetary institution "research Institute of obstetrics and gynecology them. D. O. Otta " (St. Petersburg, Russia)
9. FGBOU VPO "Petrozavodsk state University" (Petrozavodsk, Russia)
10. Irkutsk state medical University (Irkutsk, Russia)
11. Federal state budgetary scientific institution "Irkutsk scientific center of surgery and traumatology" (Irkutsk, Russia)
12. Federal STATE Autonomous educational institution national research UNIVERSITY "Belgorod state national research University" (Belgorod, Russia)

Abstract:APPROVED BY THE XVI CONGRESS Of Scientific Society of Gastroenterologists of Russia in Moscow, November 24-25, 2016 These updated guidelines (Second Edition) are based on a review and analysis of recent publications in the world and domestic literature, as well as on the authors' experience in treating patients with non-alcoholic fatty liver disease (NAFLD). Guidelines are intended for therapists and contain a description of preferred approaches to the provision of diagnostic, therapy and preventive measures in patients with NAFLD. To assess the quality of recommendations, the GRADE scale was used (Table 1), in which the strength of recommendations is divided into strong and weak, and the level of evidence has three gradations. The article is published in Russian.

• References total 80 ⇓ :: .
  1. Голованова Е. В., Лазебник Л. Б. Обзор международных и отечественных клинических рекомендаций по диагностике и лечению неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология - 2016. - № 135 (11) - С. 76-83.
  2. Голованова Е. В., Винницкая Е. В., Шапошникова Н. А., Петраков А.В, Мелькина Е. С. Эффективность нового растительного гепатопротектора Ропрен в терапии больных с неалкогольным стеатогепатитом. Экспериментальная и клиническая гастроэнтерология, № 7, 2010, стр.97-102.
  3. Голованова Е. В., Ковязина И. О., Шапошникова Н. А. Эссенциальные фосфолипиды в терапии неалкогольных стеатогепатитов. Consilium Medicum. 2007;7:23-28.
  4. Грюнграйфф К., Ламберт-Бауманн Й. Эффективность гранул L-орнитин-L-аспартата при лечении хронических заболеваний печени // Сучасна гастро-ентерологія. 2008. № 2. С. 59-67. 84.
  5. Ермолов С. Ю., Шабров А. В., Ермолова Т. В. и др. Новые подходы к диагностике и коррекции портопеченочной гемодинамики // Клиническая и экспериментальная гастроэнтерология. 2007. № 4. С. 13-16. 91.
  6. Ермолова Т. В., Яковлева Д. М. Эффективность применения L-орнитина-L-аспартата у больных стеатогепатитом // Современная гастроэнтерология и гепатология. 2012. № 1. С. 22-26. 85.
  7. Ефремов Л. И., Лазебник Л. Б., Конев Ю. В. Чревоугодие, ожирение и метаболический синдром в контексте «Семи смертных грехов». Экспериментальная и клиническая гастроэнтерология. 2013;4:56-61.
  8. Звенигородская Л. А., Конев Ю. В., Ефремов Л. И. Эволюция представлений о метаболическом синдроме. Экспериментальная и клиническая гастроэнтерология. 2011;7:4-8.
  9. Звенигородская Л. А., Мельникова Н. В., Черкашова Е. А., Самсонова Н. Г. Гиполипидемическая терапия у больных с неалкогольной жировой болезнью печени: место гепатопротекторов. Методические рекомендации ДЗ г. Москвы. Москва, 2011. С. 20.
  10. Ивашкин В. Т., Маевская М. В., Широкова Е. Н., Морозова М. А. Опыт применения препарата Эслидин® у пациентов с неалкогольной жировой болезнью печени в практике врача амбулаторного звена (Global Observation of Liver Disease treatment with Eslidin®, «GOLD») // РМЖ. 2015. № 21.
  11. Ильницкий А. Н., Максимов В. А., Каримова И. М., Позднякова Н. М. «Антивозрастная медицина: вопросы гепатологии (пособие для врачей)». ФГБОУ ДПО ИПК ФМБА России, НОГР, М., 2016
  12. Лазебник Л. Б., Звенигородская Л. А. Метаболический синдром и органы пищеварения. М.: Анахарсис, 2009. 184 с.
  13. Лазебник Л. Б., Конев Ю. В. Микробиота толстой кишки и составляющие метаболического синдрома. Экспериментальная и клиническая гастроэнтерология. 2014;5:30-39.
  14. Минушкин О. Н. (сост.) «Лаеннек в клинической практике». Учебно - методические рекомендации для терапевтов, гастроэнтерологов, курсантов цикла усовершенствования. Кафедра терапии и гастроэнтерологии ФГБУ ДПО ЦГМА УД Президента РФ. Изд. второе. М., 2015
  15. Надинская М. Ю. Гепа-Мерц: биохимические свойства и клинические эффекты. М., 2008. 87.
  16. Осипенко М. Ф., Редькина А. В., Бикбулатова Е. А. и др. Оценка L-орнитин-Lаспартата (Гепа-Мерц) в комплексном лечении неалкогольного стеатогепатита // Гастроэнтерология. Приложение к журналу Consilium Medicum. 2010. № 1. С. 35-38. 83.
  17. Раджив Джалан, Франческо Де Чиара, Вайраппан Баласубраманиян, Фаусто Андреола, Варун Кхетан, Миссимо Малаго, Миссимо Пинзани, Раджешвар П. Мукерджи, Криста Ромбоутс. Аммиак приводит к патологическим изменениям в звездчатых клетках печени, и является целью при лечении портальной гипертензии. Журнал гепатологии, 2016, том 64, с. 823-833.
  18. Селиверстов П. В., Радченко В. Г. Неалкогольная жировая болезнь печени, новые возможности терапии. Медицинский альманах. 2014;1:38-40.
  19. Чеснокова Л. В. Клинико-патогенетическое значение неалкогольной жировой болезни печени в формировании высокого сердечно-сосудистого риска у больных с метаболическим синдромом. Возможности коррекции., дисс… докт.мед.наук, 2015
  20. Bachar GN et al. Epicardial adipose tissue as a predictor of coronary artery disease in asymptomatic subjects. Am J Cardiol. 15;110:534-8. 2012.
  21. Backhed F., Ding H., Wang T., Hooper L. V., Koh G. Y., Nagy A., Semenkovich C. F., Gordon J. I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA. 2004;101(44):15718-23.
  22. Baff y G. Kupff er cells in non-alcoholic fatty liver disease: the emerging view. Hepatol 2009;51(1):212-23.
  23. Bedogni G., Bellentani S., Miglioli L., et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis BMC Gastroenterol 2006; 6:33.
  24. Bellentani S. Immunomodulating and antiapoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur. J. Gastroenterol. Hepatol. 2005;17:137-40.
  25. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006;3:318-28.
  26. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., Ponti V., Pagano G., Ferrannini E., Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005,48:634-42.
  27. Byrne C. D., Targher G. Review. NAFLD: A multisystem disease. Journal of Hepatology Vol. 62, 2015; S 47-S 64.
  28. Calori G., Lattuada G., Ragogna F., et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up // Hepatology. - 2011. - Vol. 54. - Р. 145-152,
  29. Chalasani N., Younossi Z., Lavine J. E. et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association // Am. J. Gastroenterol. - 2012. - Vol. 107. - P. 811-826.
  30. Chang C. Y., Argo C. K., Al-Osaimi A.M., Caldwell S. H. Therapy of NAFLD: antioxidants and cytoprotective agents. J. Clin. Gastroenterol. 2006;40 (Suppl 1): S 51-S 60.
  31. Chang Y., Ryu S., Sung E., Woo H. Y., Cho S. I., Yoo S. H., Ahn H. Y., Choi N. K. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut. 2009,58:1419-25.
  32. Chen M. F., Li R. C., Chen C. H., Gao X. C. Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy // Di Yi Jun Yi Da Xue Xue Bao. 2005. Vol. 25. № 6. P. 718-719. 86.
  33. Dajani et al. EPL in the management of primary NAFLD and NAFLD associated with comorbid disease // Hepatol Int. - 2013. - Vol. 7 (Suppl 1). - S 108
  34. Dam-Larsen S., Becker U., Franzmann M. B., et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scandinavian Journal of Gastroenterology 2009; 44(10): 1236-43
  35. DiBaise J.K., Zhang H., Crowell M. D., Krajmalnik-Brown R., Decker G. A., Rittmann B. E. Gut microbiota and its possible relationship with obesity. Mayo Clin. Proc. 2008;83(4):460-9.
  36. Dongiovanni P., Valenti L., Rametta R., Daly AK, Nobili V, Mozzi E, Leathart JB, Pietrobattista A, Burt AD, Maggioni M, Fracanzani AL, Lattuada E, Zappa MA, Roviaro G, Marchesini G, Day CP, Fargion S. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut. 2010;59:267-73.
  37. Drapkina OM, Korneeva ON. Metabolic syndrome and cardiovascular diseaseМетаболический синдром и сердечно-сосудистые заболевания у женщин. Насколько велико влияние пола? Сердце 2011; 10(4): 224-8
  38. Drapkina OM, Zyatenkova EV. Evaluation remodeling of the cardiovascular system and epicardial fat thickness in patients with chronic heart failure and metabolic syndrome. Ter Arkhiv 2016; 88 (2): 64-70. In Russian (Драпкина О. М., Зятенкова Е. В. Оценка ремоделирования сердечно-сосудистой системы и толщины эпикардиального жира у пациентов с хронической сердечной недостаточностью и метаболическим синдромом. Терапевтический Архив 2016; 88(2): 64-70).
  39. Drapkina OM., Korneeva ON, Ivashkin VT. A method of diagnosing insulin resistance: Patent 2553943 Russian Federation; published on 06.20.2015. Bulletin 2015; 17. In Russian (Драпкина ОМ., Корнеева О. Н., Ивашкин В. Т. Способ диагностики инсулинорезистентности: патент 2553943 Российская Федерация; опубликовано 20.06.2015. Бюллетень 2015;17
  40. Dufour J. F., Oneta C. M., Gonvers J. J., Bihl F., Cerny A., Cereda J. M., Zala J. F., Helbling B., Steuerwald M., Zimmermann A.; Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2006;4:1537-43.
  41. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016.
  42. Ermolova T., Ermolov S., Kolesnikov M. Pharmacological modifi cation of intrahepatic vascular resistance // EASL monothematic conference portal hypertension. Budapest, Hungary, 2009. Poster 19. S 85. 90.
  43. Fallo F., Dalla P. A., Sonino N., et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension // Nutr Metab Cardiovasc Dis. - 2009. - Vol. 19. - Р. 646-653.
  44. Farrell G. C., Chitturi S., K. K. Lau G., Sollano J. D.; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: Executive summary. J. Gastroenterol. Hepatol. 2007;22:775-7.
  45. Fotbolcu H., Yakar T., Duman D., Ozden K., Karaahmet T., Tigen K., Kurtoglu U., Dindar I. Aortic elastic properties in nonalcoholic fatty liver disease // Blood PressMonit. - 2010. - Vol. 15. - Р. 139-145,
  46. Fracanzani A. L., Burdick L., Raselli S., et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome //Atherosclerosis. - 2009. - Vol. 204. - Р. 521-525.
  47. Gaiani S., Avogaro A., Bombonato G. C., Bolognesi M, Amor F, Vigili de Kreutzenberg S, Guarneri G, Sacerdoti D. Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography. J. Ultrasound. 2009;12:1-5.
  48. Garinis G. A., Fruci B., Mazza A. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int. J. Obes. dvance online publication. 2010, February 23.
  49. Gastaldelli A, Kozakova M, Hњjlund K, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49:1537-44.
  50. Goland S., Shimoni S., Zornitzki T., et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment // J Clin Gastroenterol. - 2006. -Vol. 40. - Р. 949-955.,
  51. Golovanova E. V., Shaposhnikova N. A., Melkina E. S., Soultanov V. S. The hepatoprotector ropren for the treatment of patients with nonalcoholic steatohepatitis: a prospective observational study. Экспериментальная и клиническая гастроэнтерология. 2016. № 9 (133). С. 71-76.
  52. Grungreiff K., Lambert-Baumann J. Die Medizinische Welt, 2001; 52: 219-226.
  53. Gundermann et al. Essential phospholipids in fatty liver: a scientific update. Clinical and Experimental Gastroenterology 2016:9 105-117
  54. Hotamisligil G. S. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7.
  55. Iacobellis G, Barbarini G, Letizia C, Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity 2014;22(2):332-6)
  56. Karabay C. Y., Kocabay G., Kalayci A., Colak Y., Oduncu V., Akgun T., Kalkan S., Guler A., Kirma C. Gastroenterol Hepatol. - 2014. - Vol. 26. - Р. 325-331.
  57. Karajamaki A. J., Patsi O. P., Savolainen M., Kesaniemi, Y. A., Huikuri H., Ukkola O. Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study) PLoS One. - 2015. - Vol. 10. -Р. E 0142937
  58. Kircheis G., Nilius R., Held C. et al. Th erapeutic effi cacy of Lornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study // Hepatol. 1997. Vol. 25. № 6. P. 1351-1360. 88.
  59. Kotronen A., Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2008;28(1):27-38.
  60. Lee Min-Kyung, Park Hye-Jeong, Jeon Won Seon, et al. Higher association of coronary artery calcification with nonalcoholic fatty liver disease than with abdominal obesity in middle-aged Korean men: the Kangbuk Samsung Health Study // Cardiovascular Diabetology. - 2015. - Vol. 14. - Р. 88.
  61. Lin Y. C., Lo H. M., Chen J. D. Sonographic fatty liver, overweight and ischemic heart disease // W orld J Gastroenterol. - 2005. - Vol. 11. - Р. 4838-4842.,
  62. Loos R. J.F., Savage D. B. Inherited susceptibility to non-alcoholic fatty liver disease. Diabetologia. 2009;52:1000-2.
  63. Mason J. E., Starke R. D., Van Kirk J. E. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker // Prev Cardiol. - 2010. - Vol. 13 (1). - Р. 36-41.,
  64. Mirbagheri S. A., Rashidi A., Abdi S., Saedi D., Abouzari M. Liver: an alarm for the heart? // Liver Int. -2007. - Vol. 27. - Р. 891-894.,
  65. Natale F, Tedesco MA. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. Eur J Echocardiogr 2009; 10:549-55.
  66. Nekam K. Eff ect of in vivo treatment with OA (Hepamerz) on the activity and expression of SOD in cirrosis //J. Hepatol. 1991. № 11. P. 75-81. 89.
  67. Perseghin G., Lattuada G., De Cobelli F., et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver // Hepatology. - 2008. - Vol. 47. - Р. 51-58.
  68. R. Jalan, F. De Chiara et al. J. Hepatology 2016 vol.64 p.823-833.
  69. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53:372-384)
  70. Sauer A. J., Moss A. J., McNitt S., Peterson D. R., Zareba W., Robinson J. L, Qi M., Goldenberg I., Hobbs J. B., Ackerman M. J., et al. Long QT syndrome in adults // J Am Coll Cardiol. - 2007. - Vol. 49. - Р. 329-337,
  71. Silvestre O. M., Bacal F., de Souza Ramos D., Andrade J. L., Furtado M., Pugliese V., Belleti E., Andraus W., Carrilho F. J., Carneiro D’Albuquerque L. A., Queiroz Farias A. Impact of the severity of end-stage liver disease in cardiac structure and function // Ann Hepatol. - 2013, Jan-Feb. -Vol. 12(1). - Р. 85-91.
  72. Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review // J Hepatol. - 2008. - Vol. 49. -Р. 600-607
  73. Straus S. M., Kors J. A., De Bruin M. L., van der Hooft C. S., Hofman A., Heeringa J., Deckers J. W., Kingma J. H., Sturkenboom M. C., Stricker B. H., et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults // J Am Coll Cardiol. - 2006. - Vol. 47. - Р. 362-367
  74. Sun Ling and LU Shu-zheng. Association between non-alcoholic fatty liver disease and coronary artery disease severity // Chinese Medical Journal. - 2011. - Vol. 124 (6). -Р. 867-872.
  75. Targher G., Bertolini L., Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease // Diabetes Care. - 2006. - Vol. 29. - Р. 1325-1330
  76. Targher G., Day C.P, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease // N Engl J Med. - 2010. - Vol. 363. - Р. 1341-1350.
  77. Targher G., Valbusa F., Bonapace S., Bertolini L., Zenari L., Pichiri I., Mantovani A., Zoppini G., Bonora E., Barbieri E., et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes // Nutr Metab Cardiovasc Dis. - 2014. - Vol. 24. - Р. 663-669
  78. Targher G., Valbusa F., Bonapace S., Bertolini L., Zenari L., Rodella S., Zoppini G., Mantovani W., Barbieri E., Byrne C. D. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes // PLoS One. - 2013. - Vol. 8. - Р. e57183.,
  79. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease // Hepatology - 2005. - Vol. 42. - Р. 473-480.,
  80. Yilmaz Y. Liver function tests: Association with cardiovascular outcomes // World J Hepatol. - 2010. - Vol. 2 (4). - Р. 143-145.

Full text is published :
NONALCOHOLIC FATTY LIVER DISEASE: CLINIC, DIAGNOSTICS, TREATMENT (Recommendations for therapists, 2nd edition). Experimental and Clinical Gastroenterology Journal. 2017;138(02):22-37
Read & Download full text

1. Volgograd State Medical University (Volgograd, Russian Federation)

Keywords:non-alcoholic fatty liver disease,chronic heart failure,carbohydrate and fat metabolism,fatty liver index (FLI-index) index of fibrosis (NFS-index),ultrasonographic class of liver damage

Abstract:The aim of the study was to determine the relationship between the presence of disorders of carbohydrate and lipid metabolism with the structural changes of the liver in patients with ischemic chronic heart failure and non-alcoholic fatty liver disease. Materials and methods. The study included 120 patients aged 45 to 65 years old with I-III functional class chronic heart failure, myocardial infarction from 6 to 12 months. All patients had symptoms of metabolic syndrome and diabetes mellitus type 2. Patients analyzed anthropometric data, blood pressure measurement, evaluation of the content of visceral fat, level of liver markers damage, carbohydrate and lipid metabolism by conventional laboratory techniques; HOMA insulin resistance index was calculated by Mattews D. and metabolic index by Roitberg G. E.; perform calculations steatosis index (FLI) and liver fibrosis (NFS), liver ultrasonography. Results: In patients with chronic heart failure and non-alcoholic fatty liver disease FLI - index and NFS - index significantly correlated with higher levels of LDL cholesterol and triglyceride levels, decrease of HDL cholesterol and high metabolic index. Increasing FLI-index significantly correlated with the percentage of visceral fat. The level of glycated hemoglobin was significantly higher in the group with initial ultrasonographic evidence of NAFLD. FLI - index significantly correlated with level of GGT, whereas the NFS - index correlated with level of alkaline phosphatase in the group IB - IC ultrasonic classes of hepatic steatosis. Conclusion: we have identified a relationship between disorders of carbohydrate and lipid metabolism with the structural changes of the liver in patients with ishemic chronic heart failure and non-alcoholic fatty liver disease.

• References total 26 ⇓ :: .
  1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia, 2016, vol. 59, pp. 1121-1140.
  2. Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования наблюдения DIREGL 01903). Рос журн гастроэнтерол гепатол колопроктол., 2014, Т. 24, № 4, С. 32-38.
  3. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. DigestiveandLiverDisease, 2015, vol. 47, pp. 181-190.
  4. Kanwar P., Nelson J. E., Yates K., et al. Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastro, 2016, vol. 3, pp. 1-9.
  5. Yang, K. C. et al. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance. Sci. Rep., 2016, vol. 6, 27034; doi: 10.1038/srep27034 (2016).
  6. Friis-Liby I., Aldenborg F., Jerlstad P., et al. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand. J. Gastroenterol., 2004, vol. 39, pp. 864-869.
  7. Bellentani S., Bedogni G., Tiribelli C. Liver and heart: A new link? - ALT Predicts Heart Disease. Journal of Hepatology, 2008, vol. 49, pp. 300-302.
  8. Туркина С. В., Косивцова М. А., Шилина Н. Н., Стаценко М. Е. Функциональное состояние печени при нарушении микроциркуляции у больных хронической сердечной недостаточностью и сахарным диабетом 2 типа. Материалы Межрегиональной научно-образовательной конференции кардиологов и терапевтов. Специальный выпуск журнала Кардиоваскулярная терапия и профилактика, 2015, - С. 120-121.
  9. Yılmaz E. The diagnostic role of ultrasonograhyy in liver streatosis. The Turkish Journal of Gastroenterology, 1999, vol. 2, pp. 96-100.
  10. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. Практическая медицина, 2010, № 5 (44), с. 81-101.
  11. Ройтберг Г. Е., Дорош Ж. В., Шархун О. О. и др. Возможности применения нового метаболического индекса при оценке инсулинорезистентности в клинической практике. Рациональная фармакотерапия в кардиологии,2014, № 10 (3), с. 264-274.
  12. Bedogni G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 2006, vol. 6, pp. 33-38.
  13. Angulo P. The NAFLD Fibrosis Score: A Noninvasive System ThatIdentifies Liver Fibrosis in Patients with NAFLD. HEPATOLOGY, 2007, vol. 45, № 4, - pp.846-854.
  14. Ekstedt M., Franzen L. E., Mathiesen U. L. et al. Survival and causes of death in patients with elevated liver enzymes associated with non-alcoholic fatty liver disease. J. Hepatol., 2006, vol. 44 (Suppl. 2), pp.40-41.
  15. Adams L. A., Talwalkar J. A. Diagnostic evaluation of nonalcoholic fatty liver disease. J. Clin. Gastroenterol., 2006, vol. 40 (3 Suppl. 1)., pp. 34-38.
  16. Day C. P. James O. F. Steatohepatitis: a tale of two ‘hits’? Gastroenterology, 1998, vol. 114, № 4, pp. 842-845.
  17. Yamaguchi K., Yang L., McCall S. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with non-alcoholic steatohepatitis. Hepatology, 2007, vol. 45, pp. 1366-1374.
  18. Kantartzis K., Peter A., Machicao F. et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospho- lipase 3 gene. Diabetes, 2009, vol. 58, pp. 2616-2623.
  19. Shen J., Wong G. L., Chan H. L. et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Alimentary Pharmacology and Therapeutics, 2014, vol. 39, pp. 532-539.
  20. Ruttmann E., Brant L. J., Concin H. et al. Glutamyltransferase as a Risk Factor for Cardiovascular Disease Mortality. Circulation, 2005, vol.112, pp. 2130-2137.
  21. Dhingra R., Gona P., Wang T. J. et al. Serum g-GlutamylTransferase and Risk of Heart Failure in the Community. ArteriosclerThrombVascBiol., 2010, vol. 30, pp. 1855-1860.
  22. Wannamethee S. G., Whincup P. H., Shaper A. G., Lennon L. Naveed Sattarγ-Glutamyltransferase, Hepatic Enzymes, and Risk of Incident Heart Failure in Older Men. ArteriosclerThrombVasc Biol., 2012, vol. 32, pp. 830-835.
  23. Kozakova M., Palombo C., Eng M. P. et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology, 2012, vol. 55(5), pp. 1406-1415.
  24. Atar A. I., Yilmaz O. C., Akin K. et al. Association between gamma-glutamyltransferase and coronary artery calcification. Int J Cardiol, 2013, vol. 167, pp. 1264-1267.
  25. Звенигородская Л. А., Хомерики С. Г., Егорова Е. Г. Морфологические изменения печени при инсулинорезистентности. Русский медицинский журнал, 2008, Том 16, № 4, С. 161-165.
  26. Ballestri S., Lonardo A., Romagnoli D. et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver International, 2012, vol. 32, pp. 1242-1252.

Full text is published :
THE LIVER MORPHOLOGY IN NONALCOHOLIC FATTY LIVER DISEASE DEPENDING ON THE DEGREE OF ABNORMALITIES OF CARBOHYDRATE AND LIPID METABOLISM IN PATIENTS WITH CORONARY ARTERY DISEASE AND HEART FAILURE. Experimental and Clinical Gastroenterology Journal. 2017;138(02):38-44
Read & Download full text

1. Federal State Budget Educational Institution of Higher Education «Stavropol State Medical University» Health Ministry of Russian Federation (Stavropol, Russian Federation)

Keywords:nonalcoholic fatty liver disease,nonalcoholic steatohepatitis,liver fibrosis,adhesion molecules,immunoglobulins superfamily

Abstract:Aim of the work was to study relationship of molecules of immunoglobulins superfamily with histological variants of nonalcoholic fatty liver disease. Material and methods. Blood levels of parameters of immunoglobulins superfamily (ICAM-1, VCAM-1, PECAM-1) were studied in 40 patients (23 men, 17 women) with histologically proven nonalcoholic fatty liver disease in relationship with morphological changes in liver. Severe liver steatosis was revealed in 47.5 % of patients, nonalcoholic steatohepatitis was observed in 57.5 % of cases, moderate and severe liver fibrosis was present in 70 % of patients. The control group included 60 healthy volunteers. Results. The blood concentration of all adhesion molecules was increased in nonalcoholic fatty liver disease. The levels of ICAM-1 and VCAM-1 in blood increased and levels of PECAM-1 decreased with intensifying of fatty liver infiltration, reaching extreme values in cases of severe steatosis. Positive correlation between ICAM-1 and degree of steatosis was determined. In patients with parameters of nonalcoholic steatohepatitis score (NAS-II) of 5 and more points levels of ICAM-1 and VCAM-1 in blood were higher, than in group of patients with the minimal values of scale. Positive correlation of ICAM-1 and VCAM-1 with values of nonalcoholic steatohepatitis score was detected. Levels of ICAM-1, VCAM-1 and PECAM-1 in blood increased with intensifying of hepatic fibrotic changes and were maximal in severe fibrosis. Positive correlation of ICAM-1, VCAM-1 and PECAM-1 with fibrosis score was registered. Conclusion. Definition of adhesion molecules profile in nonalcoholic fatty liver disease allows to ascertain expressiveness of morphological changes and to stratify patients on groups with various morphological activity and liver fibrosis.

• References total 27 ⇓ :: .
  1. Du J., Ma Y. Y., Yu C. H., Li Y. M. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis // World. J. Gastroenterol. - 2014. - Vol. 20, № 2. - P. 569-577.
  2. Younossi Z. M., Koenig A. B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. - 2016. - Vol. 64, № 1. - P. 73-84.
  3. Promrat K., Kleiner D. E., Niemeier H. M. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis // Hepatology. - 2010. - Vol. 51. - P. 121-129.
  4. Гилязова Г. И., Мухорамова И. С., Руденко Ю. А., Корой П. В. Роль молекул адгезии в иммунном ответе // Вестник молодого ученого. - 2012. - № 2. - С. 21-27.
  5. Sookoian S., Castaño G. O., Burgueño A. L. et al. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease // Atherosclerosis. - 2010. - Vol. 209, № 2. - P. 585-591.
  6. Thakur M. L., Sharma S., Kumar A. et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians // Atherosclerosis. - 2012. - Vol. 223, № 2. - P. 507-511.
  7. VanSaun M. N., Mendonsa A. M., Gorden D. L. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease // PLoS ONE. - 2013. - Vol. 8, № 9. - Р. e73054.
  8. Mosa T. E., Shehatta A. S., Khayyal A. A. et al. High serum levels of endothelial adhesion molecules E-selectin, ICAM-1 and VCAM in fatty liver patients // Asian. J. Biochem. - 2011. - Vol. 6. - P. 160-170.
  9. Söderberg C., Marmur J., Eckes K. et al. Microvesicular fat, intercellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis // APMIS. - 2011. - Vol. 119, № 7. - P. 412-420.
  10. Weghuber D., Roden M., Franz C. et al. Vascular function in obese children with non-alcoholic fatty liver disease // Int. J. Pediatr. Obes. - 2011. - Vol. 6, № 2. - P. 120-127.
  11. Borghi-Scoazec G., Collardeau-Frachon S., Dumortier J., Scoazec J.-Y. Perisinusoidal fibrosis is associated with changes in sinusoidal endothelial cell (SEC) phenotype suggestive of a transdifferentiation process // J. Hepatol. - 2010. - Vol. 52, Suppl. 1. - S. 356.
  12. Lv P., Luo H. S., Zhou X. P. et al. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway // Arch. Med. Res. - 2007. - Vol. 38, № 1. - P. 15-27.
  13. Корой П. В., Ягода А. В., Гилязова Г. И., Мухорамова И. С. Медиаторы межклеточных взаимодействий и гистологические проявления хронической вирусной патологии печени // Росс. журн. гастроэнтерол., гепатол., колопроктол. - 2014. - № 5. - С. 22-28.
  14. Корой П. В., Мухорамова И. С., Ягода А. В. Молекулы адгезии и гистологическая картина при хронических вирусных заболеваниях печени // Мед. вестник Северного Кавказа. - 2012. - № 2. - С. 48-51.
  15. Anderson N., Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis // Pharmacol. Rev. - 2008. - Vol. 60, № 3. - P. 311-357.
  16. Thabut D., Tazi K. A., Bonnefont-Rousselot D. et al. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats // Hepatology. - 2007. - Vol. 46. - P. 1893-1906.
  17. Musso G., Gambino R., De Michieli F. et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH // Hepatology. - 2008. - Vol. 47. - P. 1167-1177.
  18. Kawasuji A., Hasegawa M., Horikawa M. et al. L-selectin and intercellular adhesion molecule-1 regulate the development of Concanavalin A-induced liver injury // J. Leukoc. Biol. - 2006. - Vol. 79, № 4. - P. 696-705.
  19. Nagarajan P., Kumar M. J. M., Venkatesan R. et al. Genetically modified mouse models for the study of nonalcoholic fatty liver disease // World. J. Gastroenterol. - 2012. - Vol. 18, № 11. - P. 1141-1153.
  20. Goel R., Boylan B., Gruman L. et al. The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis // Am. J. Physiol. Gastrointest. Liver. Physiol. - 2007. - Vol. 293. - P. G1205-1214.
  21. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults // Aliment. Pharmacol. Ther. - 2011. - Vol. 34. - P. 274-285.
  22. Kukla M., Zwirska-Korczala K., Gabriel A. et al. Soluble platelet-endothelial cell adhesion molecule-1 and soluble vascular cell adhesion molecule-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy // Therap. Adv. Gastroenterol. - 2009. - Vol. 2, № 2. - P. 79-90.
  23. Ip E., Farrell G., Hall P. et al. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice // Hepatology. - 2004. - Vol. 39, № 5. - P. 1286-1296.
  24. Thakur V., Pritchard M. T., McMullen M. R., Nagy L. E. Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding // Am. J. Physiol. Gastrointest. Liver. Physiol. - 2006. - Vol. 290, № 5. - Р. G998-1007.
  25. Tomizawa A., Hattori Y., Kasai K., Nakano Y. Adiponectin induces NFkappaB activation that leads to suppression of cytokine-induced NF-kappaB activation in vascular endothelial cells: globular adiponectin vs. high molecular weight adiponectin // Diab. Vasc. Dis. Res. - 2008. - Vol. 5. - P. 123-127.
  26. Гейвандова Н. И., Ягода А. В., Фалеева О. В., Корой П. В. Гормоны жировой ткани и гистологическая картина печени при хроническом гепатите С // Клин. перспективы гастроэнтерол., гепатол. - 2012. - № 4. - С. 17-22.
  27. Ягода А. В., Корой П. В. Функциональная активность тромбоцитов и печеночный фиброз при хронической вирусной патологии печени. Возможности неинвазивной диагностики // Экспер. клин. гастроэнтерол. - 2006. - № 5. - С. 73-76.

Full text is published :
POSITIVE CORRELATION OF THE LEVEL OF MOLECULES OF SUPERFAMILY IMMUNOGLOBULINS ICAM-1, VCAM-1 AND PECAM-1 WITH THE INDEX OF FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE. Experimental and Clinical Gastroenterology Journal. 2017;138(02):45-51
Read & Download full text

1. I. M. Sechenov First Moscow State Medical University (Moscow, Russian Federation)
2. Federal Research and Clinical Centre of Physical-Chemical Medicine (Moscow, Russian Federation)

Keywords:chronic hepatitis C,cepeginterferon alpha 2b,simeprevir,liver elastometry,recombinant HCV RF1 2k / 1b

Abstract:The features of the application of pegylated interferon - Сepeginterferon alfa2b (cepeg-IFN) on the results of treatment of 20 patients with chronic hepatitis C in outpatient practice. The analysis of the clinical, biochemical, virological data and transient liver elastometry on the background of antiviral therapy with cepeg-IFN. Based on these data is justified is not the worst in comparison with foreign analogues the efficacy and safety of the original domestic product for the treatment of patients with chronic hepatitis C, not previously treated with antiviral therapy, without a high degree of fibrosis or cirrhosis. Demonstrated clinical example of treatment failure associated with infection with a recombinant virus 2k1b and proposes an approach to the diagnosis of this variant infection

• References total 12 ⇓ :: .
  1. EASL Recommendations on Treatment of Hepatitis C 2015. J. Hepatol. 2015;63(1):199-236.
  2. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol (2016), Ссылка активна 05.01.2017. Доступно по: http://dx.doi.org/10.1016/j. jhep.2016.09.001
  3. Lavanchy D. The global burdgen of hepatitis C. Liver Int 2009; 29 (Suppl 1):74-81.
  4. Sheppard C. W., Finelli L., Alter M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis 2005; 5:558-67
  5. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. Инфекционная заболеваемость в Российской Федерации за январь - декабрь 2015года (по данным формы № 1 «Сведения об инфекционных и паразитарных заболеваниях»). Ссылка активна на 05.09.2016. Доступно по: http://rospotrebnadzor.ru/activities/statisticalmaterials/statictic_details.php? ELEMENT_ID=5525
  6. Ghany M. G., Nelson D. R., Strader D. B., Thomas D. L., Seeff L. B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatol 54:1433-44
  7. Sarrazin C., Christophe Hezode Ch., Zeuzem S., JeanMichel Pawlotsky J. M. Antiviral strategies in hepatitis C virus infection. Hepatol 2012; 88-100.
  8. Ющук Н. Д., Знойко О. О., Дудина К. Р. и соавт. Социально-экономическое бремя гепатита С: методология оценки и трудности расчета в Российской Федерации. Ссылка активна на 05.09.16. Доступно по: http://www.healtheconomics.ru/item/14159-sotsialno-ekonomicheskoe-bremya-gepatita-s-metodologiya-otsenki-i-trudnosti-rascheta-v-rossijskoj-federatsii
  9. Маевская М. В., Знойко О. О., Климова Е. А. Лечение больных хроническим гепатитом С препаратом цепэгинтерферон альфа-2b в сочетании с рибавирином (Итоговые результаты рандомизированного сравнительного клинического исследования). РЖГГК. 2014;2(24):53-64.
  10. Kalinina O., Norder H., Mukomolov S., Magnius L. O. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg // J Virol. 2002 Apr; 76 (8): 4034-4043. DOI: 10.1128/jvi.76.8.4034-4043.2002.
  11. Шахгильдян И. В., Михайлов М. И., Онищенко Г. Г. Характеристика отдельных групп высокого риска заражения вирусами гепатитов В, С и D. Дальневосточный журнал инфекционных болезней. 2004; 5: 3-112.
  12. Hedskog C, Doehle B, Chodavarapu K, Gontcharova V, Crespo Garcia J, De Knegt R, et al. Characterization of hepatitis C virus inter-genotypic recombinant strains and associated virologic response to sofosbuvir/ribavirin. Hepatology. 2014 Aug 7

Full text is published :
THE EFFI CACY AND SAFETY OF COMBINATION THERAPY OF CHRONIC HEPATITIS C WITH CEPEGINTERFERON ALPHA 2B, REBETOL AND SIMEPREVIR. Experimental and Clinical Gastroenterology Journal. 2017;138(02):52-55
Read & Download full text

1. North-Western State Medical University of Mechnikov (St. Petersburg, Russian Federation)

Keywords:chronic hepatitis,regenerative therapy,lipid metabolism,non-alcoholic fatty liver disease

Abstract:Chronic hepatitis is a common socially significant pathology in the world. One of the manifestations of chronic hepatitis B is a violation of lipid metabolism, affecting the course and progression of the underlying disease. Despite holding a large number of studies on the correction of lipid status in patients with chronic hepatitis, treatment of lipid disorders problem remains urgent. In this regard, the aim of our study was to evaluate the effect of combination therapy with the mononuclear fraction of blood compared with standard therapy on the dynamics of lipid metabolism in patients with chronic hepatitis.

• References total 15 ⇓ :: .
  1. Аутоиммунные заболевания печени: клиника, диагностика, лечение / Е. В. Голованова и др. // Экспериментальная и клиническая гастроэнтерология- 2015. - Вып.119, № 7. - С. 97-107
  2. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение / Л. Б. Лазебник и др. // Экспериментальная и клиническая гастроэнтерология- 2015. - Вып.119, № 7. - С. 85-96
  3. Неалкогольный стеатогепатит и билиарный сладж у лиц с метаболическим синдромом / В. Г. Радченко и др. // Терапевтический архив- 2016. - № 9. С. 78-83
  4. Приходько Е. М., Селиверстов П. В., Радченко В. Г. Возможности регенеративной терапии в лечении больных хроническим гепатитом // Гастроэнтерология Санкт-Петербурга- 2016. - № 1-2. М.27
  5. Пути верификации неалкогольной жировой болезни печени / П. В. Селиверстов и др. // Врач- 2015. - № 10. С. 53-55
  6. Хронические заболевания печени в практике врача терапевта / Д. Б. Цурцумия и др. // Ремедиум Приволжье-2016. - № 9. С. 22-23
  7. Grisham J. W. A mophologic study of deoxyribonucleic acid synthesis and cell proliferation in regenerating liver; autoradiography with thymidine-H3 / J. W. Grisham // Cancer Res. - 1962. - V. 22. - P. 842-849.
  8. Growth factors increase retroviral transduction but decrease clonogenic potential of umbilical cord blood CD 34+ cells / Corrias M. V. et al. // Haematologica. - 1998. - V. 83. - P. 580-6.
  9. Hepatic stem cells: inside and outside the liver? / Alison M. R. et al. // Cell Prolif. - 2004 - Vol.37. -P.1-21
  10. High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitor and precursor cells by adenovirus vectors / Frey B. M. et al. // Blood. - 1998.-V. 91.-P. 2781-92.
  11. Hepatocytes derived from bone marrow stem cells demonstrated polyploidization / Forbes S. J. et al. // J. Hepatology. - 2001. - Vol. 34. (Suppl. 1). - P. 20-21.
  12. Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells / Vogel W. et al. // Haematologica. - 2003. - V. 88. - P. 121.
  13. Higgins GM. Experimental pathology of the liver: I. Restoration of the liver of the white rat following partial surgical removal / GM Higgins, RM Anderson // Arch Pathol. - 1931. - V. 12. - P. 186-202.
  14. Hawley T. S. Methods in Molecular Biology: Flow Cytometry Protocols, 2nd ed. / Hawley T. S., Hawley R. G., Totowa, N.J. - Humana Press Inc., 2004. - P. 434.
  15. The role of the telomere test in predicting the efficacy of therapy in patients of nonalcoholic fatty liver disease / Е. Prihodko at all. // Internationaler Kongress Fachmesse «Euromedica Hannover 2015». Р. 67.

Full text is published :
THE MONONUCLEAR FRACTION OF BLOOD REGENERATIVE THERAPY OF LIPID METABOLISM IN CHRONIC HEPATITIS. Experimental and Clinical Gastroenterology Journal. 2017;138(02):56-61
Read & Download full text

1. Astrakhan State Medical University (Astrakhan, Russian Federation)

Keywords:chronic hepatitis,liver cirrhosis,tumor necrosis factor,soluble receptors of tumor necrosis factor II type

Abstract:The Aim was to investigate of clinical and diagnostic value of change of concentration of tumor necrosis factor (TNF) and also soluble receptors II type of tumor necrosis factor (sTNF-RII) in chronic hepatitis (CH) and liver cirrhosis (LC). Material and methods. 65 CH and 64 LC patients and 25 healthy volunteers were included in the investigation. TNF and sTNF-RII concentrations were assessed by the ELISA method. Results. The average TNF level in CH and LC was authentically (p<0,05) increased in comparison with the donors (84.12±10.92 IU/ml and 138.14±19.98 IU/ml cons 23.54±6.02 IU/ml). The sTNF-RII concentration in CH and LC was significantly (p<0,05) increased in comparison with the norm (in CH 7.33±0.32 IU/ml, in LC 13.15±2.19 IU/ml and in control 3.54±0.39 IU/ml). The TNF and sTNF-RII levels were significantly (p<0,05) increased in viral CH and LC in comparison with the alcoholic etiology and norm. The TNF and sTNF-RII increasing associated with the activity of inflammation and severity of LC class on the Child-Pugh score.

• References total 16 ⇓ :: .
  1. Козлова И. В., Пахомова А. Л. Практическая гастроэнтерология: руководство для врачей в 2 ч. - М.: Дрофа, 2010, 495 с.
  2. Комаров Ф. И., Осадчук М. А., Осадчук A. M. Практическая гастроэнтерология. - M.: МИА, 2010, 480с.
  3. Стрижаков А. Н., Герадзе В. Н. Современное состояние проблемы цирроза печени. Российский журнал гастроэнтерологии, гепатологии и колопроктологии, 2009, Т. 19, № 1, С. 87-88
  4. Bell B. P., Manos M. M., Zaman A. et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am. J. Gastroenterol., 2008, V. 103, P. 2727-2736.
  5. Ивашкин В. Т., Шульпекова О. Ю., Лукина Е. А. Классические провоспалительные цитокины и их биологические эффекты при заболеваниях печени. Молекулярная медицина, 2003, № 3, С. 34-43.
  6. Кетлинский С. А., Симбирцев А. С. Цитокины /СПб: Фолиант,2008.-552с.
  7. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol., 2014, 61(6), Р. 1385-96.
  8. Tilg H., Kaser A., Mosher A. R. How to modulate inflammatory cytokines in liver diseases. Liver Int., 2006, № 9, P. 1029-39.
  9. Ягода А. В., Гейвандова Н. И., Хубиев Ш. М., Цупрунова Д. С. Фактор некроза опухоли при хронических вирусных гепатитах: патогенетическая роль, пути фармакологической коррекции. Иммунология, 2000, № 2, С. 36-38.
  10. Астахин А. В., Левитан Б. Н., Афанасьев С. С. и соавт. Уровень фактора некроза опухоли-а и интерлейкина-4 в сыворотке крови больных хроническим гепатитом // Журнал микробиологии, эпидемиологии, иммунобиологии, 2004, № 2, С. 46-50
  11. Булатова И.А, Третьякова Ю. И., Щёкотова А. П. и соавт. Влияние фактора некроза опухоли альфа и полиморфизма его гена (RS 1800629) на тяжесть и прогрессирование хронического гепатита и язвенного колита.// Экспериментальная и клиническая гастроэнтерология, 2016, № 3 (127), www.elibrary.ru/pic/1pix.gifС. 9-14
  12. Mourtzikou A., Alepaki M., Stamouli M. et al. Evaluation of serum levels of IL-6, TNF-α, IL-10, IL-2 and IL-4 in patients with chronic hepatitis. Inmunologia, 2014, V 33, № 2, С. 41-50.
  13. Diez-Ruiz A., Tilz G. P., Zangerle R. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur. J. Haematol., 1995, V 54, № 1, P. 8-14.
  14. Esteve E., Botas P., Delgado E. Soluble TNF-alpha receptor 2 produced by alternative splicing is paradoxically associated with markers of liver injury. Clin. Immunol., 2007, V 123, № 1, P. 89-94.
  15. Левитан Г. Б., Астахин А. В., Ларина Н. Н., Левитан Б. Н. Растворимые рецепторы фактора некроза опухолей типа II и этиология хронических гепатитов и циррозов печени. Астраханский медицинский журнал, 2010, Т. 5, № 3, С. 41-44.
  16. Shawky A. F., Nehal H. E., Nagwa A. M., Osama M. A. Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIα in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma. Hepat. Mon. 2014,14 (9): e19346.

Full text is published :
TUMOR NECROSIS FACTOR AND ITS SOLUBLE RECEPTORS II TYPE IN CHRONIC HEPATITIS AND LIVER CIRRHOSIS. Experimental and Clinical Gastroenterology Journal. 2017;138(02):62-66
Read & Download full text

1. I. M. Sechenov First Moscow State Medical University (Moscow, Russian Federation)

Keywords:gastroesophageal reflux disease,non-erosive and erosive form,refractory form,nitric oxide synthase,endothelin-1,quality of life,the type of attitude to the disease

Abstract:Revealed clinical and psycho-physical manifestations, especially the pathogenesis, endoscopic and morphological pattern of mucosal pathology Gastroesophageal Zone in elderly patients with erosive and non-erosive form of gastroesophageal reflux disease. A total of 226 patients studied nosology. Applied clinical, endoscopic, morphological, immunohistochemical methods. Increasing the number and functional activity of the stomach and esophagus APUD cell producing nitric oxide synthase and endothelin-1 in patients in comparison with comparison groups, suggests their main pathogenic factor of the disease. Cell hyperplasia cells secreting nitric oxide synthase and endothelin-1, more than twice, there is the formation of refractory form of the disease.

• References total 10 ⇓ :: .
  1. Васcерман Л. И., Иовлев Б. В., Карлова Э. Б. и соавт. Психологическая диагностика отношения к болезни // пособие для врачей. - 2005. - 32с.
  2. Ивашкин В. Т. Гастроэзофагеальная рефлюксная болезнь. Рекомендации по диагностике и лечению / Трухманов А. С., Шептулин А. А., Баранская Е. К., Лапина Т. Л., Сторонова О. А., Кайбышева В. О./. - М., - 2013. - 20 с.
  3. Маев И. В., Самсонов А. А., Андреев Н. Г. Симптом изжоги: привычный дискомфорт или серьезная проблема?//Фарматека. -2011. -№ 10.
  4. Осадчук М. А., Осадчук А. М., Балашов Д. В. и соавт. Рефрактерная форма гастроэзофагеальной рефлюксной болезни: клинико-эндоскопические, функциональные и морфофункциональные критерии //Росс. журн. гастроэнтерол., гепатол., колопроктол. - 2011. - № 2. - С. 30-36.
  5. Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, Koike T, Hongo M, Chiba T, Kinoshita Y. Acid-Related Symptom Research Group. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;14:1273-1283.
  6. Herregods T. V., Troelstra M., Weijenborg P. W., Bredenoord A. J., Smout A. J. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterol Motil. 2015 Jun 18. doi: 10.1111/nmo.12620.
  7. Sugimoto M, Uotani T, Ichikawa H, Andoh A, Furuta T. Gastroesophageal Reflux Disease in Time Covering Eradication for All Patients Infected with Helicobacter pylori in Japan. Digestion. 2016;93(1):24-31. doi: 10.1159/000441741.
  8. Takeshima F, Hashiguchi K, Onitsuka Y, Tanigawa K, Minami H, Matsushima K, Akazawa Y, Shiozawa K, Yamaguchi N, Taura N, Ohnita K, Ichikawa T, Isomoto H, Nakao K. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life. Med Sci Monit. 2015 Dec 31;21:4111-21
  9. Ware J. E. The MOS 36-item short form health survey (SF-36): conceptual framework and item selection / J. E. Ware, C. D. Sherbourne // Medical Care. 1992. Vol. 30. P. 473-483.
  10. Yoshiyasu Kono, Ryuta Takenaka, Yoshiro Kawahara, Hiroyuki Okada, Keisuke Hori, Seiji Kawano, Yasushi Yamasaki, Koji Takemoto, Takayoshi Miyake, Shigeatsu Fujiki, and Kazuhide Yamamoto. Chromoendoscopy of gastric adenoma using an acetic acid indigocarmine mixture. World J Gastroenterol. May 7, 2014; 20(17): 5092-5097.

Full text is published :
INCREASED FUNCTIONAL ACTIVITY OF APUD CELL OF THE ESOPHAGUS AND THE STOMACH AT THE GASTROESOPHAGEAL REFL UX IN THE ELDERLY. Experimental and Clinical Gastroenterology Journal. 2017;138(02):67-70
Read & Download full text

1. North-Western Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)
2. St.-Petersburg State Medical University named after I. P. Pavlov (St. Petersburg, Russian Federation)

Keywords:lung cancer,chemotherapy,gastrointestinal complaints

Abstract:Chemotherapy, used in patients with oncological diseases, leads to damage of a mucous membrane of gastrointestinal tract. 60 % of patients treated by chemotherapy have stools disorders. The article presents the data of the study of the severity of gastrointestinal complaints in patients with lung cancer, chemotherapy, the nature of the influence appointed in the schemes of the treatment of lung cancer anticancer drugs, shows the possibilities of correction of the revealed violations. Using of probiotics in these patients leads to decrease of gastrointestinal complains.

• References total 11 ⇓ :: .
  1. Гржибовский А. М. Анализ количественных данных для двух независимых групп / А. М. Гржибовский // Экология человека. - 2008. - № 2. - С. 54-61.
  2. Ионова Т. И., Новик А. А. Исследование качества жизни у больных лимфомами // Вестн. Межнац. центра исследования КЖ. - 2006. - № 7-8. С. 121-137.
  3. Казюлин А. Н., Кучерявый Ю. А., Гайдамака Е. В. Факторы риска и частота токсического поражения желудочно-кишечного тракта при проведении противоопухолевой химиотерапии рака молочной железы // Газета «Новости медицины и фармации». - 2007. - № 226 - С. 15-17.
  4. Карпинская Н. П. Колонизационная резистентность слизистой оболочки полости рта у больных раком легкого в условиях противоопухолевой химиотерапии: Автореферат диссертации на соискание ученой степени к. м. н.: 14.00.16 / Карпинская Наталья Павлиновна. - Томск, 2006. - 18 с.
  5. Новик А. А., Ионова Т. И. Руководство по исследованию качества жизни в медицине. - СПб.: Издательский Дом «Нева»; М.: «ОЛМА-ПРЕСС Звездный мир», 2002.-320с., Новик А. А., Ионова Т. И., Кайнд П. Концепция исследования качества жизни в медицине. - СПб.: ЭЛБИ, 1999. - 140 с.
  6. Поддубная И. В., Орел Н. Ф., Смирнова Н. Б., Егоров Г. Н. Побочные реакции и осложнения противоопухолевой терапии и борьба с ними // Химиотерапия онкологических заболеваний. - М., 2000. - С. 336-359.
  7. Чиссов В. И., Старинский В. В., Петрова Г. В. Состояние онкологической помощи населению России в 2009 году. М.: ФГУ «МНИОИ им. П. А. Герцена Росмедтехнологий». - 2010. - 196 с.
  8. Cancer Statistics, 2009 / A. Jemal, R. Siegal, E. Ward, Y. Hao, J. Xu, M. Thun // CA Cancer J. clin. - 2009. - № 59. - P. 275-249. 111.
  9. Sánchez-Lara K, Ugalde-Morales E, Motola-Kuba D, Green D. Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapy. Br J Nutr. - 2012, Jun. 1 - Vol. 2. - P. 1-4. 165.
  10. van Vliet MJ, Tissing WJ, Dun CA, Meessen NE, Kamps WA, de Bont ES, Harmsen HJ. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin. Infect. Dis. - 2009. - Vol. 49(2) - P. 262-270. 179.
  11. World cancer report 2008 / Ed. by P. Boyle, B. Levin - WHO, Lyon, IARC: - 2008. - 511 p. 184.

Full text is published :
CORRECTION OF DIGESTIVE DISORDERS BY PROBIOTICS IN LUNG CANCER PATIENTS WITH CHEMOTHERAPY. Experimental and Clinical Gastroenterology Journal. 2017;138(02):71-76
Read & Download full text

1. Saratov State Medical University of V. I. Razumovsky (Saratov, Russian Federation)

Keywords:Acute intestinal infections,the treatment of acute intestinal infections,succinate-containing drugs,Reamberinpharmacoeconomic efficiency

Abstract:The aim of the research: the study of features of clinical course of acute intestinal infections (AII) on the background of coronary heart disease (CHD), diabetes (D), mental and behavioral disorders on the background of alcohol consumption (AC); development of pathogenetic therapy for these comorbid conditions by means of using succinate-containing drugs. Materials and Methods: 197 patients with AII (without associated diseases, and with CHD, D, AC) were examined in dynamics. The patients received conventional infusion therapy or 1,5 % solution of Reamberin at 10 mg per 1 kg of body weight. Pharmacoeconomic efficiency of using Reamberin was calculated. Results: Associated pathology determines more severe course of AII and possibility of complications, including decompensation of chronic disease. Introduction of Reamberin in the infusion therapy for patients with AII enabled proved decrease in the number of existing symptoms in all groups by the second day of treatment, as well as decrease in the persistence of the main symptoms of AII. The absence of cases of decompensation of chronic disease in patients receiving Reamberin was noted, in cases of their presence on the background of traditional therapy. Specific economy as a result of using Reamberin in the complex therapy of AII was 23383,5 rubles mainly due to the reduction of the duration of the disease and more rapid vocational rehabilitation. Conclusion: The presence of comorbid pathology affects the typical manifestations of AII, which requires optimization of therapy. The findings show the ability of Reamberin to influence the clinical course of AII, including in cases with associated diseases, by reducing the persistence of the main symptoms of the disease as well as the number of complications associated with decompensation of chronic conditions. High cost-effectiveness of using Reamberin in the treatment of AII, along with a proven positive clinical effect, is an important argument in favor of the widespread use of the succinate-containing drugs in clinical practice.

• References total 30 ⇓ :: .
  1. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2015 году»
  2. State report “The state of sanitary and epidemiological welfare of the population in the Russian Federation in 2015”
  3. Здравоохранение в России. 2015: Стат.сб. Росстат. - М., 2015. - 174 с.
  4. Health care in Russia. 2015: Stat.sb. Rosstat. - M., 2015. - 174 p.
  5. Тихонова Е. О., Ляпина Е. П., Перминова Т. А., Сатарова С. А. Особенности течения острых кишечных инфекций на фоне психических и поведенческих расстройств, вызванных употреблением алкоголя. Инфекционные болезни. Приложение 1: Материалы VIII Ежегодного Всероссийского Конгресса по инфекционным болезням (Москва, 28-30 марта 2016 г.), 2016, т. 14, с. 279.
  6. Tikhonovа E. O., Lyapina E. P., Perminovа T. A., Satarovа S. A. A course of acute intestinal infections in the background of mental and behavioral disorders caused by alcohol. Infectious diseases. Application 1: Materials of the VIII-th Annual All-Russian Congress on Infectious Diseases (Moscow, 28-30 March 2016), 2016, vol.14, p. 279.
  7. Реамберин: клинические и экспериментальные исследования / Реферативный сборник научных работ, процитированных в PubMed (база данных медицинских и биологических публикаций) в 2012 году / Под редакцией В. Г. Белова. - СПб., 2013. - 150 с. Reamberin: clinical and experimental studies / Abstract collections of scientific papers cited in PubMed (base of medical and biological publications data) 2012 / Edited by V. G. Belov. - SPb., 2013. - 150 p.
  8. Заплутанов В. А., Романцов М. Г., Тихонова Е. О. и соавт. Особенности течения острых кишечных инфекций с оценкой эффективности патогенетической терапии. Антибиотики и химиотерапия, 2012, т. 57, № 9-10, cc. 17-24.
  9. Zaplutanov V. A., Romantsov M. G., Tikhonova E. O. et al. A course of acute intestinal infections with the assessment of the effectiveness of pathogenetic therapy. Antibiotics and chemotherapy, 2012, vol.57, № 9-10, pp. 17-24.
  10. Шульдяков А. А., Блинникова Е. Н., Соболева Л. А., Савинова Г. А. Оптимизация метаболической терапии хронических вирусных гепатитов. Вестник Санкт-Петербургской государственной медицинской академии им. И. И. Мечникова, 2009, № 1, cc. 156-159.
  11. Shuldyakov A. A., Blinnikova E. N., Soboleva L. A., Savinova G. A. Optimization of the metabolic therapy of chronic viral hepatitis. Bulletin of St. Petersburg State Medical Academy of I. I. Mechnikov, 2009, № 1, pp.156-159.
  12. Зубарева С. В., Шульдяков А. А., Трубецков А. Д. и соавт. Метаболическая терапия при хроническом бруцеллезе как средство коррекции эндотоксикоза и функциональных нарушений миокарда. Вестник Санкт-Петербургской государственной медицинской академии им. И. И. Мечникова, 2008, № 3, cc. 93-95.
  13. Zubareva S. V., Shuldyakov A. A., Trubetskov A. D. et al. Metabolic therapy in chronic brucellosis as a means of correcting endotoxemia and myocardial function disorders. Bulletin of St. Petersburg State Medical Academy of I. I. Mechnikov, 2008, № 3, pp. 93-95.
  14. Маркевич П. С., Даниленко С. Ю., Янкин А. В. Роль препарата «Цитофлавин» в клинической практике. Бюллетень ВСНЦ СО РАМН, 2010, № 3 (73), cc. 109.
  15. Markevitch P. S., Danilenko S. Y., Yankin A. V. The role of the drug “Citoflavin” in clinical practice. Bulletin ESSC SB RAMS, 2010, № 3 (73), pp. 109.
  16. Markevitch P. S., Danilenko S. Y., Yankin A. V. The role of the drug “Citoflavin” in clinical practice. Bulletin ESSC SB RAMS, 2010, № 3 (73), pp. 109.
  17. http://www.sartfoms.ru/tarifagreement/2016/20160129/Tarif_29_01_16_P5.1.pdf
  18. http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/accounts
  19. http://srtv.gks.ru/wps/wcm/connect/rosstat_ts/srtv/ru/statistics/standards_of_life/5ee59800447992ada430e520d 5236cbc
  20. Маржохова М. Ю. Уровень веществ низкой и средней молекулярной массы как показатель эндотоксикоза у больных пищевыми токсикоинфекциями, протекающими на фоне хронического алкоголизма. Материалы. юбилейной Российской научной конференции с международным. участием, посвященной 175-летию со дня рождения С. П. Боткина. Под ред. Б. В. Гайдара. - СПб., 2007, с. 266.
  21. Marzhohova M. Yu. The level of low and medium molecular weight substances as an indicator of endotoxemia in patients with foodborne diseases occurring on a background of chronic alcoholism. Materials of anniversary Russian scientific conference with the international participation, devoted to 175th anniversary of S. P. Botkin. Ed. Gaidar B. V. - St. Petersburg, 2007, p. 266.
  22. Оковитый С. В., Суханов Д. С., Заплутанов В. А., Смагина А. Н. Антигипоксанты в современной клинической практике. Клиническая медицина, 2012, № 9, сс. 63-68. Okovity S. V., Sukhanov D. S., Zaplutanov V. A., Smagina A. N. Antihypoxants in modern clinical practice. Clinical medicine, 2012, № 9, pp. 63-68.
  23. Коновалова М. С. Янтарная кислота против воспалений и опухолей. - СПб.: Весь, 2005. - 128 с.
  24. M. S. Konovalova. Succinic acid against inflammations and tumors. - SPb.: Ves`, 2005. - p.128.
  25. Тихонова Е. О., Ляпина Е. П., Шульдяков А. А. Изучение эффективности патогенетической терапии больных острыми кишечными инфекциями с использованием сукцинатсодержащего препарата Реамберина. Экспериментальная и клиническая фармакология, 2013, 76(1), pp. 11-13.
  26. Tikhonova E. O., Lyapina E. P., Shuldyakov A. A. Efficiency of the pathogenetic therapy of patients with acute intestinal infections with the use of succinate-containing drug Reamberin. Experimental and Clinical Pharmacology, 2013, 76 (1), pp. 11-13.
  27. Скоромец А. А., Никитина В. В., Барышев Б. А. Влияние реамберина на сосудисто-тромбоцитарное и плазменно-коагуляционное звенья гемостаза в плазме крови у доноров in vitro. Вестник Санкт-Петербургской медицинской академии им. И. И. Мечникова, 2003, 4, cc. 132-136.
  28. Skoromets A. A., Nikitina V. V., Baryshev B. A. Influence of reamberin on vascular-platelet and plasma coagulation parts of hemostasis in the blood plasma of donors in vitro. Bulletin of the St. Petersburg Medical Academy of I. I. Mechnikov, 2003, 4, pp. 132-136.
  29. Плоскирева А. А., Горелов А. В., Жучкова С. Н., Бондарева А. В. и др. Современные подходы к интенсивной терапии острых кишечных инфекций у детей. Инфекционные болезни, 2012, т. 10, № 1, сс. 50-55.
  30. Ploskireva A. A., Gorelov A. V., Zhuchkova S. N., Bondarev A. V. and others. Current approaches to intensive therapy of acute intestinal infections in children. Infectious Diseases, 2012, vol.10, № 1, pp. 50-55.

Full text is published :
REAMBERIN IN THE COMPLEX THERAPY OF ACUTE INTESTINAL INFECTIONS. Experimental and Clinical Gastroenterology Journal. 2017;138(02):77-85
Read & Download full text

1. Saratov State Medical University n. a. Razumovsky (Saratov, Russian Federation)

Keywords:nonalcoholic fatty liver disease,colonopathy,intestine,colon,microbiome

Abstract:The review presents modern data on epidemiology, risk factors, mechanisms of nonalcoholic fatty liver disease, role of intestine and colon microbiome in the development of nonalcoholic fatty liver disease.

• References total 41 ⇓ :: .
  1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther,2011,34, pp.274-285.
  2. Weib J., Rau M., Geier A. Non-Alcoholic Fatty Liver Disease. Epidemiology, Clinical Course, Investigation, and Treatment.Dtsch Arztebl Int,2014, 111,26, pp. 447-52.
  3. Sanyal Aj. NASH: A global health problem.Hepatol Res, 2011,41, pp. 670-674.
  4. Williams CD, Stengel J, Asike MJ et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.Gastroenterology,2011,140, pp.124-131.
  5. Захаренко С. М., Фоминых Ю. А., Мехтиев С. Н. Инфекции, микробиота кишечника человека и метаболический синдром. Эффективная фармакотерапия. Гастроэнтерология, 2011, № 3, c. 14-22.
  6. Козлова И. В., Пахомова А. Л. Современный пациент гастроэнтерологического профиля: штрихи к клиническому портрету. Экспериментальная и клиническая гастроэнтерология,2015,№ 6,118, c. 4-10.
  7. Анисимова Е. В., Козлова И. В., Волков С. В., Мещеряков В. Л. Патология органов пищеварения при ожирении(обзор).Саратовский научно-медицинский журнал, 2011,№ 7,4, c.851-856.
  8. Ивашкин В. Т., Маевская М. В., Павлов Ч. С. и соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии,2016,№ 2, с. 1-20.
  9. П. В. Селивёрстов. Неалкогольная жировая болезнь печени: от теории к практике. Архивь внутренней медицины, Заболевания гепатобилиарного тракта, 2015,№ 1,21, c.19-26.
  10. Петухов В. А. Липидный дистресс-синдром (диагностика и принципы лечения): Пособие для врачей/В.А.Петухов/Под ред.В.С.Савельева.-М.: ВЕДИ,2003.-88 с.: ил.
  11. Я. Л. Тюрюмин, В. А. Шантуров, Е. Э. Тюрюмина. Физиология обмена холестерина (обзор). Бюллетень ВСНЦ СО РАМН, 2012,№ 2,84, ч. 1, с. 153-158.
  12. Li Tand, Chiang J. Bile Acid Signaling in Liver Metabolism and Diseases. Journal of Lipids, 2012, pp.1-9.
  13. Gadaleta RM, Cariello M, Sabbà C, Moschetta A. Tissue-specific actions of FXR in metabolism and cancer.Biochim Biophys Acta, 2015,185,1, pp.30-39.
  14. Сафонова М. В., Козлова И. В., Овсянникова В. В., Кветной И. М. Патология толстой кишки у больных с циррозом печени. Клиническая медицина, 2012,№ 90,10, с. 44-48.
  15. Takaki A, Kawai D, Yamamoto K. Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH). Int. J Mol Sci, 2013, 14, pp. 20704-20728.
  16. Miele L, Valenza V, la Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 2009, 49, pp.1877-1887.
  17. Сафонова М. В., Козлова И. В. Патология желудочно-кишечного тракта при хронических диффузных заболеваниях печени. -Саратов 2012;156 с.
  18. Костюкевич О. И. Дислипидемия у кардиологических пациентов с сочетанным поражением ЖКТ: новое в патогенезе и современные возможности терапии.Русский медицинский журнал, 2011,14, с. 870-873.
  19. Буторова Л. И. Холестероз желчного пузыря: патогенез, клиника, диагностика, принципы консервативной терапии: пособие для врачей / Нац. о-во по изуч. пробл. липидологии и ассоциир. метабол. заболеваний, Секция липидологии и ассоциир. мета- бол. заболеваний Российского науч. мед. о-ва терапевтов, Шк. липидологии и ассоциир. метабол. заболеваний. - М.: Форте принт, 2012; 52 с.
  20. Frazier Th., DiBaise J, Craig J. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. Journal of Parenteral and Enteral Nutrition, 2011, vol. 35, no. 5, pp.15-20.
  21. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc, 2008, vol.83, no.4, pp. 460-469.
  22. Урсова Н. И. Жировая дистрофия печени при метаболическом синдроме в практике врача-педиатра.Лечащий врач,2010, № 1, с. 14-17.
  23. Немцов В. И. Нарушения состава кишечной микрофлоры и метаболический синдром.Клинико-лабораторный консилиум, 2010, № 1(32), с. 4-13.
  24. Henao-Mejia, J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature, 2012, vol. 482, pp. 179-185.
  25. Гейвандова Н. И., Ягода А. В., Бабашева Г. Г., Нигиян З. В. Роль эндотоксинемии в развитии неалкогольного стеатогепатита. Российские Медицинские Вести, 2015, Том XX, № 2, с. 41-46.
  26. Гейвандова Н. И., Ягода А. В., Бабашева Г. Г., Нигиян З. В. Роль эндотоксинемии в развитии неалкогольного стеатогепатита. Российские Медицинские Вести, 2015, Том XX, № 2, с. 41-46.
  27. Селиверстов П. В., Радченко В. Г., Сафроненкова И. Г., Ситкин С. И. Взаимоотношения печени и кишечника на фоне дисбаланса микрофлоры толстой кишки.Гастроэнтерология Санкт-Петербурга, 2010,2-3, с. 15-18.
  28. М. Е. Семендяева. Неалкогольная жировая болезнь печени как медицинская и социальная проблема. Клиническая практика, 2012,№ 2, с. 71-80.
  29. А. О. Буеверов, П. О. Богомолов. Неалкогольная жировая болезнь печени: обоснование патогенетической терапии. Клинические перспективы гастроэнтерологии, гепатологии,2009, № 1, с. 3-9.
  30. Ткаченко Е. И., Успенский Ю. П., Белоусова Л. Н. и др. Неалкогольная жировая болезнь печени и метаболический синдром: единство патогенетических механизмов и подходов к лечению.Экспериментальная и клиническая гастроэнтерология, 2008,№ 2, с. 92-96.
  31. Козлова И. В., Пахомова А. Л. Практическая гастроэнтерология. Руководство для врачей: учебное пособие для системы послевузовского профессионального образования врачей. Москва, 2010, Том Ч. 1.
  32. Шемеровский К. А. Неалкогольная жировая болезнь печени.Русский медицинский журнал, 2015,№ 26, с. 1528-1530.
  33. Чихачева Е. А., Селиверстов П. В., Ситкин С. И., Добрица В. П., Радченко В. Г. Тактика коррекции нарушений микробиоценозов кишечника в комплексной терапии больных циррозом печени. Терапевтический архив, 2014,№ 4, с. 52-57.
  34. Е. А. Чихачева, Л. А. Тетерина, П. В. Селиверстов, В. П. Добрица, В. Г. Радченко. Пробиотики в комплексной терапии хронических заболеваний печени. Гастроэнтерология Санкт-Петербурга, 2012,№ 4, с. 11-15.
  35. Л. В. Журавлёва, О. В. Лахно, О. И. Цивенко. Опыт применения пробиотиков при неалкогольной жировой болезни печени.Сусчасна Гастроентерологiя, 2014,№ 6,80, с. 105-112.
  36. Балукова Е. В., Успенский Ю. П. Место пробиотиков в лечении неалкогольной жировой болезни печени. Русский медицинский журнал, 2012,№ 15, с. 788.
  37. Lirussi F., Mastropasqua E., Orando S., Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007.
  38. Scalera A, Dario Di Minno M, Tarantino G. What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J Gastroenterol,2013, vol.19, no.33, pp. 5402-5420.
  39. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.Hepatology, 2010, vol. 52, pp. 1836-1846.
  40. Wong V. W., Won G. L., Chim A.M et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study.Ann Hepatol, 2013, vol. 12, no.2, pp. 256-262.
  41. Hughes PA, Harrington AM, Castro J et al. Sensory neuro-immune interactions differ between Irritable Bowel Syndrome subtypes. Gut, 2012, vol.62, pp.1456-1465.

Full text is published :
NONALCOHOLIC FATTY LIVER DISEASE AND COLON: THE RELATIONSHIP AND INTERACTION. Experimental and Clinical Gastroenterology Journal. 2017;138(02):86-91
Read & Download full text

1. Federal state educational institution of higher education «Kuban State Medical University» Russian Ministry of Health (Krasnodar, Russian Federation)

Keywords:peritonitis,microsomal system,sodium hypochlorite

Abstract:The urgency of the problems caused by the high frequency of its occurrence. The role of the liver microsomal system and the gastrointestinal tract, where there is a cytochrome P450 biotransformation processes required for xenobiotics and endobiotics that will optimize the diagnosis of peritonitis, the development of methods of prevention and treatment. This review is an attempt to synthesize and analyze accumulated information about the pathogenesis of peritonitis, which dictates the need to revise the overall treatment strategy and the search for new effective methods of detoxification. It studies the processes of microsomal oxidation, will provide additional information relevant to the prediction of the adaptive capacity of the organism in the syndrome of endogenous intoxication. Therefore, one of these areas is the problem of simulation (catalytic and electrochemical) processes in the liver and the gastrointestinal tract.

• References total 29 ⇓ :: .
  1. Арчаков А. И. Микросомальное окисление. - М.: Наука, 1975. - 327 с.
  2. Ковалев И. Е., Полевая О. Ю. Биохимические основы иммунитета к низкомолекулярным химическим соединениям. - М: Наука, 1985. - 304 с.
  3. Комаров Б. Д., Лужников Е. А., Шиманко И. И. Хирургические методы лечения острых отравлений. - М.: Медицина, 1981. - 271 с.
  4. Кузнецова Э. Э., Горохова В. Г., Горохов А. Г. и др. Микросомальное окисление в физиологических и патологических условиях // Бюллетень ВСНЦ СО РАМН. - 2007. - № 4. - С. 170-180.
  5. Кукес В., Ших Е., Сычев Д. Изучение биотрансформации лекарственных средств - путь к повышению эффективности и безопасности фармакотерапии. // Врач. - 2007. - № 1. - С. 6-8.
  6. Курбонов К. М., Даминова Н. М. Печеночная недостаточность при послеоперационном желчном перитоните // Анналы хирургии. - 2007. - № 4. - С. 70-72.
  7. Курбонов К. М., Даминова Н. М., Шарипов Х. Ю. Эндотелиальная недостаточность при послеоперационном желчном перитоните // Анналы хирургии. - 2008. - № 3. - С. 66-69.
  8. Лопаткин Н. А., Лопухин Ю. М. Эфферентные методы в медицине. - М.: Медицина. - 1989. - 352 с.
  9. Новожеева Т. П., Смагина М. И., Черевко Н. А., Фатеева С. Н. Бензобарбитал и фторбензобарбитал - индукторы фенобарбиталового типа монооксигеназной системы печени // Бюллетень сибирской медицины. - 2011. - № 5. - С. 79-81.
  10. Петухов В. А., Сан Д. А., Миронов А. В. Эндотоксиновая агрессия и дисфункция эндотелия при синдроме кишечной недостаточности в экстренной хирургии органов брюшной полости: причинно-следственные связи // Анналы хирургии. - 2006. - № 5. - С. 27-33.
  11. Савельев В. С., Лубянский В. Г., Петухов В. А. Дисметаболические последствия синдрома кишечной недостаточности в абдоминальной хирургии. // Анналы хирургии. - 2005. - № 6. - С. 39-42.
  12. Савельев В. С., Петухов В. А., Каралкин А. В. и др. Синдром кишечной недостаточности в ургентной абдоминальной хирургии: новые методические подходы к лечению // Трудный пациент. - 2005. - № 4. - С. 30-37.
  13. Савельев В. С., Петухов В. А. Перитонит и эндотоксиновая агрессия. - Москва, 2012. - 326с.
  14. Сергиенко В. И., Васильев Ю. Б. Гринберг В. Д. Мартынов А. К. Удаление токсинов из организма с помощью электрохимического окисления // Вопросы мед. химии. - 1991. - № 2. - С. 74-78.
  15. Сибиряк С. В., Сергеева С. А., Крыжановский С. А., Красилова И. Л. Динамика изменений макрофагальной активности, метаболической активности печени и уровня кортизола в сыворотке на фоне введения бактериальных иммуностимуляторов // Бюлл. экспер. биол. мед. - 1996 - № 2. - С. 177-180.
  16. Сибиряк С. В. Цитокины как регуляторы цитохром Р-450-зависимых монооксигеназ. Теоретические и прикладные аспекты // Цитокины и воспаление. - 2003. - № 2. - С. 12-21.
  17. Тутельян В. А., Кравченко Л. В. Микотоксины (медицинские и биологические аспекты) М.: Медицина, 2002. - 608 с.
  18. Федоровский Н. М. Непрямая электрохимическая детоксикация (Окисление крови и плазмы в лечении хирургического эндотоксикоза). - М.: Медицина, 2004. - 143 с.
  19. Хакимов Э. Э., Аширметов А. Х., Краковский М. Э. Состояние микросомальной окислительной системы печени крыс при остром каловом перитоните // Вопросы мед. химии. - 1990. - № 3. - С. 52-54.
  20. Хрупкин В. И., Алексеев С. А. Синдром энтеральной недостаточности у больных с распространенным перитонитом: оценка степени тяжести и исхода процесса // Вестник хирургии. - 2004. - № 2. - С. 46-49.
  21. Черешнев В. А., Юшков Б. Г., Климин В. Г., Лебедева Е. В. Иммунофизиология - Екатеринбург: УроРАН, 2002. - 258 с.
  22. Щербаков В. М., Тихонов А. В. «Изоформы цитохрома Р-450 печени человека» М., АО «Биохимические технологии». - 1995. - С. 18-23.
  23. Alican I., Kubes P. Acritical role nitric oxide in intestinal barrier function and dysfunction. // Amеr. J. Physiol. - 1996. - Vol. 270. - P. 225-227.
  24. Berg R. D. Bacterial translocation from the intestines // Jikken Dobutsu. - 1985. - Vol. 34. - № 1. - P. 1-16.
  25. Castancio A. M., Bounous G., Balzola F. The role of the intestine in pathogenesis of MOF // Riv. Ital. Nutr. Parenteral enterale. - 1990. - Vol. 8. - № 1. - P. 1-5.
  26. Conney A. H. Pharmacological implications of microsomal enzyme induction // Pharmacol. Rev. - 1967. - Vol. 19. - P. 317-366.
  27. Conney A. H. Pharmacological implications of microsomal enzyme induction // Pharmacol. Rev. - 1967. - Vol. 19. - P. 317-366.
  28. Meakins J.L, Marshall J. S. The gastrointestinal tract: the “motor” OF MSOF // Arch. Surg. - 1986. - Vol. 121. - № 2. - P. 197-201.
  29. Morgan E., Ullrich V., Daiber A. et al. Cytochromes P450 and Flavin monooxygenases tagets and souces of nitric oxide // Drug Metab. Dispos. - 2001. -Vol. 29. - P. 1366-1376.

Full text is published :
THE BIOTRANSFORMATION OF XENOBIOTICS AND ENDOBIOTICS IN PERITONITIS. Experimental and Clinical Gastroenterology Journal. 2017;138(02):92-96
Read & Download full text

1. Scientific and Educational Center of Gastroenterology and Hepatology of Saint-Petersburg University (St. Petersburg, Russian Federation)

Keywords:nonalcoholic fatty liver disease,nonalcoholic steatohepatitis,treatment,S-adenosylmethionine,ademetionine,new drugs

Abstract:The aim of our research was to study the current and future trends in the treatment of nonalcoholic fatty liver disease. This review presents recommendations of leading hepatology Associations in the treatment of nonalcoholic fatty liver disease (NAFLD). The article describes the results of research at the development of new directions in the treatment of this disease and rates the of the most promising drugs. Conclusions. There are several new drugs for treatment of nonalcoholic fatty liver disease under clinical trials today, but further research is needed to assess their long-term efficacy and safety. One of the more pathogenetically grounded drugs for the treatment of NAFLD is ademetionine.

• References total 45 ⇓ :: .
  1. Ивашкин В. Т., Драпкина О. М., Маев И. В. и соавт. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в российской федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015, № 6, С. 31-41.
  2. Charlton M. R., Burns J. M., Pedersen R. A. et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology, 2011, vol.141, pp. 1249-1253.
  3. Wong R. J. Aguilar M., Cheung R. et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology, 2015, vol.148, no. 36 pp. 547-555.
  4. Younossi Z. M., Koenig A. B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, vol.64, no.1, pp.73-84.
  5. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology, 2016, vol. 64, no. 6, pp.1388-1402.
  6. Практические рекомендации Всемирной Гастроэнтерологической Организации: неалкогольная жировая болезнь печени и неалкогольный стеатогепатит [Электронный ресурс]. Режим доступа: http://www.worldgastroenterology.org/guidelines/global-guidelines/nafld-nash (последнее обращение 21.02.2017).
  7. Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012, vol. 55, no. 6, pp. 2005-2023.
  8. Ивашкин В. Т., Маевская М. В., Павлов Ч. С. и соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского Общества по Изучению Печени и Российской Гастроэнтерологической Ассоциации. Российский Журнал Гастроэнтерологии, Гепатологии, Колопроктологии, 2016, Т. 26, № 2, С. 24-42.
  9. McTigue K.M., Harris R., Hemphill B. et al. Screening and interventions for obesity in adults: summary of the evidence for the U. S. Preventive Services Task Force. Annals of International Medicine, 2003, vol.139, pp. 933-949.
  10. Trappoliere M., Tuccillo C., Federico A. et al. The treatment of NAFLD. European Review for Medical and Pharmacological Sciences, 2005, vol. 9, no. 5, pp. 299-304.
  11. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 2015, vol. 149, no. 2, pp. 367-378.
  12. Dansinger M. L., Tatsioni A., Wong J. B. et al. Meta- analysis: the effect of dietary counseling for weight loss. Annals of International Medicine, 2007, vol.147, pp. 41-50.
  13. The Look AHEAD Research Group. The look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring), 2006, vol.14, no. 5, pp. 737-752.
  14. Vilar-Gomez E., Yasells-Garcia A., Martinez-Perez Y. et al. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology, 2016, vol. 63, pp. 1875-1887.
  15. Lavine J. E., Schwimmer J. B., Van Natta M. L. et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA, 2011, vol. 305, pp. 1659-1668.
  16. Sanyal A. J., Chalasani N., Kowdley K. V. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England Journal of Medicine, 2010, vol. 362, pp. 1675-1685.
  17. Sanyal A. J., Chalasani N., Kowdley K. V. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England Journal of Medicine, 2010, vol. 362, pp. 1675-1685.
  18. Klein E. A., Thompson Jr I. M., Tangen C. M. et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 2011, vol. 306, pp. 1549-1556.
  19. Leuschner U. F., Lindenthal B., Herrmann G. et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology, 2010, vol. 52, pp. 472-479.
  20. Argo C. K., Patrie J. T., Lackner C. et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. Journal of Hepatology, 2015, vol. 62, pp. 190-197.
  21. Dongiovanni P., Petta S., Mannisto V. et al. Statin use and nonalcoholic steatohepatitis in at risk individuals. Journal of Hepatology, 2015, vol. 63, pp. 705-712.
  22. Carbone L. J., Angus P. W., Yeomans N. D. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta- analysis. Journal of Gastroenterology and Hepatology, 2016, vol. 31, pp.23-31.
  23. Musso G., Gambino R., Cassader M., Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology, 2010, vol. 52, pp. 79-104.
  24. Rotman Y., Sanyal A. J. Current and upcoming pharmacotherapy for non- alcoholic fatty liver disease. Gut, 2016, vol. 66, no. 1, pp. 180-190.
  25. Ratziu V., Harrison S. A., Francque S. et al. Elafibranor, an agonist of the peroxisome proliferator activated receptor alpha and delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology, 2016, vol. 150, pp. 1147-1159.
  26. ClinicalTrials.gov [Электронный ресурс]. Режим доступа: http://www. clinicaltrials.gov (последнее обращение 21.02.2017).
  27. Neuschwander-Tetri B.A., Loomba R., Sanyal A. J. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, 2015, vol. 385, no. 9972, pp. 956-965.
  28. Safadi R., Konikoff F. M., Mahamid M.et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology, 2014, vol. 12, no. 12, pp. 2085-2091.
  29. Mukhopadhyay P., Horvath B., Rajesh M. et al. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. Journal of Hepatology, 2017, vol. 66, no. 3, pp. 589-600.
  30. Balistreri W. F. Eschewing the Fat: What’s on the Horizon for Treating NASH? 2015 [Электронный ресурс]. Режим доступа: / http://www.medscape.com/viewarticle/841001 (последнее обращение 21.02.2017).
  31. Copple B. L., Jaeschke H., Klaassen C. D. Oxidative stress and the pathogenesis of cholestasis. Seminars in Liver Disease, 2010, vol. 30, no. 2, pp. 195-204.
  32. Avila M. A., Berasain C., Torres L. et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 2000, vol. 33, no. 6, pp. 907-914.
  33. Colell A., Garcia-Ruiz C., Miranda M. et al. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology, 1998, vol. 115, no. 6, pp. 1541-1551.
  34. Song Z., Zhou Z., Chen T. et al. S-adenosylmethionine (SAMe) protects against acute alcohol induced hepatotoxicity in mice. The Journal of Nutritional Biochemistry, 2003, vol. 14, no. 10, pp. 591-597.
  35. Vendemiale G., Altomare E., Trizio T. et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scandinavian Journal of Gastroenterology, 1989, vol. 24, no. 4, pp. 407-415.
  36. Martinez-Chantar M.L., Corrales F. J., Martinez-Cruz L.A. et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. The FASEB Journal, 2002, vol. 16, no. 10, pp. 1292-1294.
  37. Webster C. R., Boria P., Usechak P., Anwer M. S. S-adenosylmethionine and cAMP confer differential cytoprotection against bile acid-induced apoptosis in canine renal tubular cells and primary rat hepatocytes. Journal of Veterinary Pharmacology and Therapeutics, 2002, vol. 3, no. 4, pp. 474-484.
  38. Huang X. F., Zhao W. Y., Huang W. D. et al. FXR and liver carcinogenesis. Acta Pharmacologica Sinica: English edition, 2015, vol. 36, no. 1, pp. 37-43.
  39. Anstee Q. M., Goldin R. D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. International Journal of Experimental Pathology, 2006, vol. 87, no. 1, pp. 1-16.
  40. Cano A., Buque X., Martinez-Una M. et al. Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice. Hepatology, 2011, vol. 54, no. 6, pp. 1975-1986.
  41. Kalhan S. C., Edmison J., Marczewski S. et al. Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. Clinical Science, 2011, vol. 121, no. 4, pp. 179-189.
  42. Tao Guo, Lei Chang, Yusha Xiao, Quanyan Liu. S-Adenosyl-L-Methionine for the Treatment of Chronic Liver Disease: A Systematic Review and Meta-Analysis. PLOS ONE, 2015, vol. 10, no. 3, e0122124.
  43. Барановский А. Ю., Райхельсон К. Л., Марченко Н. В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии, 2010. Т. 9, № 1, C. 3-10.
  44. Барановский А. Ю., Райхельсон К. Л., Марченко Н. В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии, 2010. Т. 9, № 1, C. 3-10.
  45. Prospective multicenter observational program to characterize the patient population with cholestasis in chronic liver disease due to non-alcoholic liver disease (hepatic steatosis) receiving Heptral in the Russian Federation / Abbott Laboratories (Abbott) / Program Report R&D/13/766 / Protocol P12-715 (информация предоставляется по запросу компании Abbott LLC)

Full text is published :
NONALCOHOLIC FATTY LIVER DISEASE: PROSPECTS FOR TREATMENT. Experimental and Clinical Gastroenterology Journal. 2017;138(02):97-102
Read & Download full text

1. Federal State Budgetary of Scientific Institution “Institution of Internal and Preventive Medicine” (Novosibirsk, Russian Federation)
2. Novosibirsk state University (Novosibirsk, Russian Federation)

Keywords:pancreatic cancer,genes,molecular pathways,targeted therapy,immunotherapy

Abstract:Pancreatic ductal adenocarcinoma (PDA) is one of the most dangerous and clinically difficult cancers. PDA is one of the diseases for which the mortality rate is almost equal to the level of morbidity. The absence of effective methods of screening, late detection are the main reasons for that. At the same surgical and therapeutic treatments are ineffective. Using different types of chemotherapy increases the life expectancy of patients with 5-7 months of gemcitabine in the treatment of one to 8,5-11 months with combination therapy. Therefore, the search for new targets for therapy is a main task in this pathology. In a review article presents the results of recent research in the field of genetics and molecular biology of PDA. Described mutations in key genes: KRAS, TP53, CDKN 2A, SMAD 4, ARID 1A and also often identify other gene defects: TGFBR 2, KDM6A, AXIN 1, ACVR 1B, PIK3CA, RNF43, GNAS, ATM, GLI3, ARID 1A and RBM10. Presents the analysis of the relationship of gene mutations with changes of their signaling pathways and the possibility of using the features of targeted therapy of PDA. The review reflects the problems of changes in immune status, participation mechanisms stromal cell component in the processes of tumor progression and metastasis, the possibility of using specific antibodies in combination chemotherapy regimens in PDA.

• References total 80 ⇓ :: .
  1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016; 66:7-30.
  2. Давыдов М. И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2012 году. М.: Издательская группа РОНЦ, 2014. - 226 с.
  3. Ryan D. P., Hong T. S., Bardeesy N. Pancreatic adenocarcinoma. N. Engl. J. Med. 2014; 371 (11): 1039-1049.
  4. Котельников А. Г., Патютко Ю. И., Трякин А. А. Клинические рекомендации по диагностике и лечению злокачественных опухолей поджелудочной железы. Москва, 2014. - 44 с.
  5. Yadav D., Lowenfels A. B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013; 144:1252-1261.
  6. Goggins M. Markers of pancreatic cancer: working toward early detection. Clin. Cancer. Res.2011;5:635-637.
  7. Makohon-Moore A., Brosnan J. A., Iacobuzio-Donahue C. A. Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med. 2013; 5: 26-37.
  8. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010; 5:1605-1617.
  9. Wong K.K, Qian Z, Le Y. The Role of Precision Medicine in Pancreatic Cancer: Challenges for Targeted Therapy, Immune Modulating Treatment, Early Detection, and Less Invasive Operations. Cancer Transl. Med. 2016; 2(2):41-47.
  10. Takai E., Yachida Sh. Genomic alterations in pancreatic cancer and their relevance to therapy. World J. Gastrointest. Oncol. 2015; 7(10): 250-258.
  11. Vaccaro V., Sperduti I., Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011; 365:768-779.
  12. Von Hoff D. D., Ervin T., Arena F. P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl. J. med. 2013; 369:1691-1703.
  13. Heestand G. M., Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget. 2015; 6:4553-4561.
  14. Sahin I. H., Iacobuzio-Donahue C.A., O’Reilly E. M. Molecular signature of pancreatic adenocarcinoma: An insight from genotype to phenotype and challenges for targeted therapy. Expert Opin. Ther. Targets. 2016; 20(3):341-359.
  15. Witkiewicz A. K., McMillan E.A., Balaji U. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 2015; 6: 6744-6755.
  16. Forbes S. A., Bindal N., Bamford S. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic acids research. 2011; 39:945-950.
  17. Catalogue of Somatic Mutations in Cancer (COSMIC) Wellcome Trust Sanger Institute; Hinxton, UK: http://www.sanger.ac.uk/cosmic accessed December 1, 2014.
  18. Jamieson N. B., Chang D. K., Grimmond S. M., Biankin A. V. Can we move towards personalised pancreatic cancer therapy? Expert Rev. Gastroenterol. Hepatol. 2014; 8(4): 335-338.
  19. Mohammed S., Van Buren G. 2nd, Fisher W. E. Pancreatic cancer: advances in treatment. World J. Gastroenterol. 2014; 20(28): 9354-9360.
  20. Okano K., Suzuki Y. Strategies for early detection of resectable pancreatic cancer. World J. Gastroenterol. 2014; 20(32): 11230-11240.
  21. Григорьева И. Н., Ефимова О. В., Суворова Т. С., Тов Н. Л. Генетические аспекты РПЖ. Экспериментальная и клиническая гастроэнтерология 2014; 110 (10):70-76.
  22. Григорьева И. Н. Острый и хронический панкреатит. Изд. «Наука», Новосибирск. 2010. 101 с.
  23. Jancík S., Drábek J., Radzioch D., Hajdúch M. Clinical relevance of KRAS in human cancers. Biomed. Biotechnol. 2010; 5:150960.
  24. Heldin C.-H., Moustakas A. Role of Smads in TGFβ signaling. Cell Tissue Res. 2012; 5: 21-36.
  25. Lüttges J., Galehdari H., Bröcker V. et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC 4 genes during pancreatic carcinogenesis. Am. J. Pathol. 2001; 5:1677-1683.
  26. Calhoun E. S., Hucl T., Gallmeier E. et al. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res. 2006; 66 (16):7920-7928.
  27. Mermel C. H., Schumacher S. E., Hill B. et al. GISTIC 2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12 (4): R 41.
  28. Biankin A. V., Waddell N., Kassahn K. S. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491(7424): 399-405.
  29. Vakiani E., Solit D. B. KRAS and BRAF: drug targets and predictive biomarkers. J. Pathol. 2011; 223: 219-229.
  30. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer. 2003; 3:459-465.
  31. Alagesan B., Contino G., Guimaraes A. R. et al. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin. Cancer Res. 2015; 21(2): 396-404.
  32. Infante J. R., Fecher L. A., Falchook G. S. et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. lancet oncology. 2012; 13:773-781.
  33. Infante J. R., Somer B. G., Park J. O. et al. A randomised, double-blind, placebo-controlled trial of rametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur. J. cancer. 2014; 50:2072-2081.
  34. Schonleben F., Qiu W., Ciau N. T. et al. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin. Cancer. Res. 2006; 12(12): 3851-3855.
  35. Wolpin B. M., Hezel A. F., Abrams T. et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 2009; 27 (2): 193-198.
  36. Heldin C-H., Miyazono K., ten Dijke P. TGF-b signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997; 390:465-471.
  37. Massague J. The TGF-beta family of growth and differentiation factors. Cell 1987; 49(4): 437-438.
  38. Ellenrieder V., Hendler S. F., Boeck W. et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 2001; 61(10): 4222-4228.
  39. Derynck R., Zhang Y., Feng X. H. Smads: transcriptional activators of TGF-beta responses. Cell.1998; 11: 95(6):737-740.
  40. Tascilar M., Skinner H. G., Rosty C. et al. The SMAD 4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2001; 7(12):4115-4121.
  41. Iacobuzio-Donahue C.A., Fu B., Yachida S. et al. DPC 4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 2009; 27(11):1806-1813.
  42. Winter J. M., Tang L. H., Klimstra D. S. et al. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD 4 expression. Ann. Surg. 2013; 258(2):331-335.
  43. Crane C. H., Varadhachary G. R., Yordy J. S. et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J. Clin. Oncol. 2011; 29(22):3037-3043.
  44. Blackford A., Serrano O. K., Wolfgang C. L. et al. SMAD 4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin. Cancer Res. 2009; 15(14):4674-4679.
  45. Casey G., Yamanaka Y., Friess H. et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett. 1993; 69(3):151-160.
  46. Polyak K., Xia Y., Zweier J. L. et al. A model for p53-induced apoptosis. Nature. 1997; 389(6648):300-305.
  47. Izetti P., Hautefeuille A., Abujamra A. L. et al. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Invest. New Drugs. 2014; 32(5):783-794.
  48. Azmi A. S., Philip P. A., Wang Z. et al. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr. Cancer Drug Targets. 2010; 10(3):319.
  49. Liggett W., Sidransky D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol.1998; 16(3):1197-1206.
  50. Stott F. J., Bates S., James M. C. et al. The alternative product from the human CDKN 2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998; 17(17):5001-5014.
  51. Caldas C., Hahn S. A., da Costa L. T., et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS 1) gene in pancreatic adenocarcinoma. Nature Genet. 1994; 8(1):27-32.
  52. Schutte M., Hruban R. H., Geradts J. et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57(15):3126-3130.
  53. Heilmann A. M., Perera R. M., Ecker V. et al. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Res. 2014; 74(14):3947-3958.
  54. Liu F., Korc M. Cdk4/6 Inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol. Cancer Ther. 2012; 11(10):2138-2148.
  55. Finn R. S., Crown J. P., Lang I. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER 2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.
  56. Allenspach E. J., Maillard I., Aster J. C., Pear W. S. Notch signaling in cancer. Cancer Biol. Ther. 2002; 1 (5): 466-476.
  57. Ranganathan P., Weaver K. L., Capobianco A. J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer. 2011; 11(5):338-351.
  58. Andersson E. R., Lendahl U. Therapeutic modulation of Notch signalling - Are we there yet? Nat. Rev. Drug. Discov. 2014; 13(5): 357-378.
  59. Lee J. Y., Song S. Y., Park J. Y. Notch pathway activation is associated with pancreatic cancer treatment failure. Pancreatology 2014; 14(1):48-53.
  60. Waddell N., Pajic M., Patch A. M. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518(7540): 495-501.
  61. Waddell N., Pajic M., Patch A. M. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518(7540): 495-501.
  62. Ikemoto T., Yamaguchi T., Morine Y. et al. Clinical roles of increased populations of Foxp3+CD 4+T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 2006; 33(4): 386-390.
  63. Yamagiwa S., Gray J. D., Hashimoto S., Horwitz D. A. A role for TGF-beta in the generation and expansion of CD 4+CD 25 + regulatory T cells from human peripheral blood. J. Immunol. 2001; 166(12):7282-7289.
  64. Blauenstein U. W. On the effects of moderate hypothermia on the acid base and electrolyte ratio in cerebrospinal fluid and arterial blood. Anaesthesist 1965; 14(12):361-366.
  65. Clark C. E., Hingorani S. R., Mick R. et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007; 67(19):9518-9527.
  66. Davis M., Conlon K., Bohac G. C. et al. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J. Immunother. 2012; 35(8):629-640.
  67. Kurahara H., Shinchi H., Mataki Y. et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 2011; 167(2): e211-219.
  68. Rucki A. A., Zheng L. Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. World J. Gastroenterol. 2014; 20(9):2237-2246.
  69. Farrow B., Albo D., Berger D. H. The role of the tumor microenvironment in the progression of pancreatic cancer. J. Surg. Res. 2008;149:319-328.
  70. Lewin C. S., Allen R. A., Amyes S. G. Mechanisms of zidovudine resistance in bacteria. J. Med. Microbiol.1990; 33:235-238.
  71. Waghray M., Yalamanchili M., di Magliano M. P., Simeone D. M. Deciphering the role of stroma in pancreatic cancer. Curr. Opin. Gastroenterol. 2013; 29:537-543.
  72. Feig C., Gopinathan A., Neesse A. et al. The pancreas cancer microenvironment. Clin. Cancer Res. 2012; 18:4266-4276.
  73. Erkan M., Michalski C. W., Rieder S. et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 2008; 6:1155-1161.
  74. Olive K. P., Jacobetz M. A., Davidson C. J. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324:1457-1461.
  75. Beatty G. L., Chiorean E. G., Fishman M. P. et al. CD 40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331:1612-1616.
  76. Heinemann V., Reni M., Ychou M. et al. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat. Rev. 2014; 40:118-128.
  77. Burris H. A., Moore M. J., Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15:2403-2413.
  78. Brahmer J. R., Tykodi S. S., Chow L. Q. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012; 366(26): 2455-2465.
  79. Beatty G. L., Chiorean E. G., Fishman M. P. et al. CD 40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331(6024): 1612-1616.
  80. Vonderheide R. H., Bajor D. L., Winograd R. et al. CD 40 immunotherapy for pancreatic cancer. Cancer Immunol. Immunother. 2013; 62(5):949-954.

Full text is published :
CANCER OF THE PANCREAS. SOME OF THE MOLECULAR AND GENETIC MECHANISMS OF CARCINOGENESIS AS A TARGET FOR THERAPY. Experimental and Clinical Gastroenterology Journal. 2017;138(02):103-109
Read & Download full text

1. Samara state medical university (Samara, Russian Federation)

Keywords:comorbid pathology,chronic obstructive pulmonary disease,Caroli ‘s disease

Abstract:Idiopathic cystic expansion of the intrahepatic ducts (Caroli’s disease) is a congenital hereditary disease, inherited as an autosomal recessive trait. To improve the prognosis in case of cholangitis appointed antibiotics. When intrahepatic stones and / or the presence of biliary sludge successfully used ursodeoxycholic acid. Described clinical case management of the patient with acute exacerbation of chronic obstructive pulmonary disease (COPD) and Caroli disease. Antibacterial COPD exacerbations correction contributed to the prevention of cholangitis with improved liver function due antiholestatic and hepatoprotective effect of ursodeoxycholic acid. Integrated approach to comorbidity status of the patient achieves the highest compliance.

• References total 14 ⇓ :: .
  1. Haubrich W. S. Caroli of Caroli’s disease. Gastroenterology 2000; 118 (3): 486.
  2. Gunay-Aygun M., Font-Montgomery E., Lukose L. et al. Characteristics of Congenital Hepatic Fibrosis in a Large Cohort of Patients With Autosomal Recessive Polycystic Kidney Disease. Gastroenterology 2012; 144 (1): 112-121.
  3. Gevers T. J.G., Inthout J., Caroli A. et al. Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data. Gastroenterology 2013; 145 (2): 357-365.
  4. Strazzabosco M., Somlo S. Polycystic liver diseaeses: congenital disorders of cholangiocyte signaling. Gastroenterology 2011; 140: 1855-1859.
  5. Sato Y., Ren X. S., Nakanuma Y. Caroli’s disease: Current knowledge of its biliary pathogenesis obtained from an orthologous rat model. Int J Hepatol. 2012;2012:107945.
  6. Sato Y., Ren X. S., Nakanuma Y. Caroli’s disease: Current knowledge of its biliary pathogenesis obtained from an orthologous rat model. Int J Hepatol. 2012;2012:107945.
  7. Kerr S. E., Barr Fritcher E. G., Campion M. B. Biliary dysplasia in primary sclerosing cholangitis harbors cytogenetic abnormalities similar to cholangiocarcinoma. Human pathology 2014; 45 (9): 1797-1804.
  8. Lewis J. T., Talwalkar J. A., Rosen C. B. et al. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J SurgPathol. 2010; 34: 27-34.
  9. Rizvi S., Gores G. J. Pathogenesis, Diagnosis and Management of Cholangiocarcinoma. Gastroenterology 2013; 145 (6): 1215-1229.
  10. Cetta F., Baldi C., Montalto G. et al. Intrahepatic gallstones associated with congenital bile duct dilatation restricted to the intrahepatic ducts (Caroli’s disease) are frequently cholesterol and sometimes resemble in shape the cast of dilated ducts. Gastroenterology 2000; 118 (4): A7.
  11. Drenth J. P., Chrispijn M., Nagorney D. M. et al. Medical and surgical treatment options for polycystic liver disease. Hepatology 2010; 52: 2223-2230.
  12. Григорьева И. Н. Билиарный сладж. РЖГГК 2009; 19 (3): 32-37. (Grigor’eva I. N. Biliary sludge. RZhGGK 2009; 19 (3): 32-37.)
  13. Ивашкин В. Т., Широкова Е. И., Маевская М. В. с соавт. Клинические Рекомендации Российской Гастроэнтерологической ассоциации Российского Общества по изучению печени по диагностике и лечению холестаза. РЖГГК 2015; 2: 41-57. (Ivashkin V. T., Shirokova E. I., Maevskaja M. V. et al. Clinical Recommendations Russian Gastroenterological Association of Russian Society for the Study of Liver for the diagnosis and treatment of cholestasis. RZhGGK 2015; 2: 41-57.).
  14. Celli B. R. Change in the BODE index reflects disease modification in COPD: lessons from lung volume reduction surgery. Chest 2006; 129 (4): 873-878.

Full text is published :
CAROLI DISEASE IN PATIENT WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Experimental and Clinical Gastroenterology Journal. 2017;138(02):110-113
Read & Download full text

1. Perm State Medical University. Acad. E. A. Wagner (Perm, Russian Federation)

Keywords:history of surgery,S.S. Yudin,gastric resection,esophagoenteroanastomosis,military field surgery,cadaveric blood,Marfan syndrome

Abstract:The purpose of the study. To present the history of the life and work of one of the greatest surgeons of modern times - S. S. Yudin. To justify the assumption of the presence of chromosomal abnormalities - Marfan’s syndrome Materials and methods. The study used bibliographical, historical-genetic and analytical methods Results. We have summarised information on the fate and scientific work of academician Sergey Sergeyevich Yudin and suggested the presence of chromosomal abnormalities - Marfan’s syndrome, as evidenced by: high growth and dolichostenomelia; hypermobility of joints; severe myopia; insufficiency of the aortic valve, the result of which was myocardial infarction. High adrenaline background, characteristic of the disease contributed to the highest health, lightning-fast reactions to events and emotional techniques of operations.

• References total 7 ⇓ :: .
  1. Кузьмин И. В., Юдин И. Ю. Академик С. С. Юдин - ссыльный хирург и вынужденный онколог: еще раз о погубленных талантах и невостребованных специалистах мирового класса // Новый хирургический архив. - 2001. - Т. 1. - № 3; www.sakharov-center.ru/asfcd/auth/?t=page&num=4860
  2. Лисиченко О. В. Синдром Марфана. Новосибирск: Наука, 1986. 164 с.
  3. Симонян К. С. Путь хирурга: Страницы из воспоминаний о С. С. Юдине: [1891-1954] / Кирилл Семенович Симонян. - М.: Медгиз, 1963. - 94 с.
  4. Тополянский В. Дело Юдина Журнал «Индекс/Досье на цензуру» 31/2011 Режим доступа http://www.index.org.ru/journal/31/15-topoljnski.html 28.11.16 10.37
  5. Трисветова Е. Л. Клиническая диагностика синдрома Марфана «Медицинские новости» 2006 № 3
  6. Эфроимсон В. П. «О биосоциальных факторах повышенной умственной активности». «Человек» - 1997 № 2-6, 1998, № 1
  7. Юдин С. С. Воспоминания М., Тончу 2012 688 с.

Full text is published :
Nechaev O.I., Palatova L.F. SERGEI SERGEEVICH YUDIN AND MARFAN SYNDROME. Experimental and Clinical Gastroenterology Journal. 2017;138(02):114-118
Read & Download full text

1. State Budget Educational Institution of Higher Professional Education (SBEI HPE) “A. I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Healthcare of Russia” (Moscow, Russian Federation)
2. I. M. Sechenov First Moscow State Medical University (St. Petersburg, Russian Federation)
3. North-Western State Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)

Abstract: Report on the work of the jubilee XVI Congress of the Scientific Society of Gastroenterologists of Russia, dedicated to the 50th anniversary of the foundation of the Society. The Congress took place in the frames of the XI National Congress of Therapists on the 24-25 November 2016 in Moscow in Crocus City Hall. 5876 physicians from 85 regions and 334 cities of the Russian Federation took part in the Congress. The article is published in Russian.

Full text is published :
Golovanova E.V., Podymova S.D., Sitkin S.I., Stefanyuk O.V. REPORT ON THE WORK OF THE XVI CONGRESS OF GSSR. Experimental and Clinical Gastroenterology Journal. 2017;138(02):119-123
Read & Download full text